References

Abrams, Keith, Deborah Ashby, and Daniel Errington. 1994. “Simple Bayesian Analysis in Clinical Trials: A Tutorial.” Controlled Clinical Trials 15 (5): 349–59. https://doi.org/10.1016/0197-2456(94)90032-9.

Adcock, C. J. 1988. “A Bayesian Approach to Calculating Sample Sizes.” The Statistician 37 (4/5): 433. https://doi.org/10.2307/2348770.

———. 1997. “Sample Size Determination: A Review.” Journal of the Royal Statistical Society, Series D (The Statistician) 46 (2): 261–83. https://doi.org/10.1111/1467-9884.00082.

Agrawal, Shipra, and Navin Goyal. 2013. “Further Optimal Regret Bounds for Thompson Sampling.” In Proceedings of the 16th International Conference on Artificial Intelligence and Statistics, 31:99–107. Proceedings of Machine Learning Research. https://arxiv.org/abs/1209.3353.

Albuquerque, Arthur M. et al. 2021. “Tocilizumab in COVID-19: A Bayesian Reanalysis of RECOVERY.” medRxiv preprint. https://doi.org/10.1101/2021.06.15.21258966.

Alexander, Brian M., Sujuan Ba, Mitchel S. Berger, Donald A. Berry, Webster K. Cavenee, Susan M. Chang, Timothy F. Cloughesy, et al. 2018. “Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.” Clinical Cancer Research 24 (4): 737–43. https://doi.org/10.1158/1078-0432.CCR-17-0764.

Alexander, Brian M., Jonathan D. Schoenfeld, and Lorenzo Trippa. 2018. “Hazards of Hazard Ratios: Deviations from Model Assumptions in Immunotherapy.” New England Journal of Medicine 378 (12): 1158–59. https://doi.org/10.1056/NEJMc1716612.

Altman, Douglas G., and Kenneth F. Schulz. 2001. “Concealing Treatment Allocation in Randomised Trials.” BMJ 323 (7310): 446–47. https://doi.org/10.1136/bmj.323.7310.446.

Angus, Derek C., Scott Berry, Roger J. Lewis, Farah Al-Beidh, Yaseen Arabi, Wilma van Bentum-Puijk, Zahra Bhimani, et al. 2020. “The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) Study: Rationale and Design.” Annals of the American Thoracic Society 17 (7): 879–91. https://doi.org/10.1513/AnnalsATS.202003-192SD.

Anscombe, F. J. 1963a. “Sequential Medical Trials.” Journal of the American Statistical Association 58 (302): 365–83. https://doi.org/10.1080/01621459.1963.10500851.

———. 1963b. “Sequential Medical Trials.” Journal of the American Statistical Association 58 (302): 365–83. https://doi.org/10.1080/01621459.1963.10500851.

Armitage, Peter. 1954. “Sequential Tests in Prophylactic and Therapeutic Trials.” Quarterly Journal of Medicine 23 (91): 255–74.

———. 1960. Sequential Medical Trials. Oxford: Blackwell Scientific Publications.

Armitage, P., C. K. McPherson, and B. C. Rowe. 1969. “Repeated Significance Tests on Accumulating Data.” Journal of the Royal Statistical Society, Series A 132 (2): 235–44. https://doi.org/10.2307/2343787.

Arnol’d, Vladimir I. 2006. “Forgotten and Neglected Theories of Poincaré.” Russian Mathematical Surveys 61 (1): 1–18.

Arrow, K. J., D. Blackwell, and M. A. Girshick. 1949. “Bayes and Minimax Solutions of Sequential Decision Problems.” Econometrica 17 (3/4): 213–44. https://doi.org/10.2307/1905525.

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Patrick R. Lawler, Ewan C. Goligher, Jeffrey S. Berger, et al. 2021. “Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.” New England Journal of Medicine 385 (9): 790–802. https://doi.org/10.1056/NEJMoa2105911.

Auer, Peter, Nicolò Cesa-Bianchi, and Paul Fischer. 2002. “Finite-Time Analysis of the Multiarmed Bandit Problem.” Machine Learning 47 (2–3): 235–56. https://doi.org/10.1023/A:1013689704352.

Babb, James, Andre Rogatko, and Shelemyahu Zacks. 1998. “Cancer Phase I Clinical Trials: Efficient Dose Escalation with Overdose Control.” Statistics in Medicine 17 (10): 1103–20. https://doi.org/10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9.

Barker, Ann D., Carolyn C. Sigman, Gary J. Kelloff, Nola M. Hylton, Donald A. Berry, and Laura J. Esserman. 2009. “I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy.” Clinical Pharmacology & Therapeutics 86 (1): 97–100.

Barnard, G. A. 1946. “Sequential Tests in Industrial Statistics.” Journal of the Royal Statistical Society, Series B 8 (1): 1–21. https://doi.org/10.2307/2983610.

Barter, Philip J., Mark Caulfield, Mats Eriksson, et al. 2007. “Effects of Torcetrapib in Patients at High Risk for Coronary Events.” New England Journal of Medicine 357 (21): 2109–22. https://doi.org/10.1056/NEJMoa0706628.

Bartlett, M. S. 1957. “A Comment on D. V. Lindley’s Statistical Paradox.” Biometrika 44 (3–4): 533–34. https://doi.org/10.1093/biomet/44.3-4.533.

Bartlett, Robert H., Daniel W. Roloff, Richard G. Cornell, Alvin F. Andrews, Patricia W. Dillon, and Joseph B. Zwischenberger. 1985. “Extracorporeal Circulation in Neonatal Respiratory Failure: A Prospective Randomized Study.” Pediatrics 76 (4): 479–87.

Bassler, Dirk, Matthias Briel, Victor M. Montori, Melanie Lane, Paul Glasziou, et al. 2010. “Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects: Systematic Review and Meta-Regression Analysis.” JAMA, 1180–87. https://doi.org/10.1001/jama.2010.310.

Bate, A., M. Lindquist, I. R. Edwards, S. Olsson, R. Orre, A. Lansner, and R. M. De Freitas. 1998. “A Bayesian Neural Network Method for Adverse Drug Reaction Signal Generation.” European Journal of Clinical Pharmacology 54 (4): 315–21. https://doi.org/10.1007/s002280050466.

Bauer, Peter, Frank Bretz, Vladimir Dragalin, Franz König, and Gernot Wassmer. 2016. “Twenty-Five Years of Confirmatory Adaptive Designs: Opportunities and Pitfalls.” Statistics in Medicine 35 (3): 325–47. https://doi.org/10.1002/sim.6472.

Bauer, P., and K. Kohne. 1994. “Evaluation of Experiments with Adaptive Interim Analyses.” Biometrics 50 (4): 1029. https://doi.org/10.2307/2533441.

Bedrick, Edward J., Ronald Christensen, and Wesley Johnson. 1996. “A New Perspective on Priors for Generalized Linear Models.” Journal of the American Statistical Association 91 (436): 1450–60.

Bellman, Richard. 1957. Dynamic Programming. Princeton University Press.

Benjamin, Daniel J. et al. 2018. “Redefine Statistical Significance.” Nature Human Behaviour 2: 6–10. https://doi.org/10.1038/s41562-017-0189-z.

Benjamini, Yoav, and Yosef Hochberg. 1995. “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.” Journal of the Royal Statistical Society: Series B (Methodological) 57 (1): 289–300.

Benjamini, Yoav, and Daniel Yekutieli. 2001. “The Control of the False Discovery Rate in Multiple Testing Under Dependency.” The Annals of Statistics 29 (4): 1165–88. https://doi.org/10.1214/aos/1013699998.

Benkeser, David, Iván Díaz, Alex Luedtke, Jodi Segal, Daniel Scharfstein, and Michael Rosenblum. 2021. “Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.” Biometrics 77 (4): 1467–81. https://doi.org/10.1111/biom.13377.

Berger, James. 2006. “The Case for Objective Bayesian Analysis.” Bayesian Analysis 1 (3): 385–402. https://doi.org/10.1214/06-BA115.

Berger, James O. 1985. Statistical Decision Theory and Bayesian Analysis. 2nd ed. New York: Springer-Verlag.

Berger, James O., and Thomas Sellke. 1987. “Testing a Point Null Hypothesis: The Irreconcilability of P Values and Evidence.” Journal of the American Statistical Association 82 (397): 112–22. https://doi.org/10.2307/2289131.

Berger, James O., and Robert L. Wolpert. 1988. The Likelihood Principle. 2nd ed. Vol. 6. IMS Lecture Notes, Monograph Series. Hayward, CA: Institute of Mathematical Statistics.

Berkson, Joseph, and Robert P. Gage. 1952. “Survival Curve for Cancer Patients Following Treatment.” Journal of the American Statistical Association 47 (259): 501–15. https://doi.org/10.2307/2281318.

Berry, Donald A. 1985. “Interim Analyses in Clinical Trials: Classical Vs. Bayesian Approaches.” Statistics in Medicine 4 (4): 521–26.

———. 1987. “Interim Analysis in Clinical Trials: The Role of the Likelihood Principle.” The American Statistician 41 (2): 117–22. https://doi.org/10.1080/00031305.1987.10475458.

———. 1989. “Ethics and ECMO.” Statistical Science 4 (4): 306–10.

———. 2006. “Bayesian Clinical Trials.” Nature Reviews Drug Discovery 5 (1): 27–36. https://doi.org/10.1038/nrd1927.

———. 2011. “Adaptive Clinical Trials: The Promise and the Caution.” Journal of Clinical Oncology 29 (6): 606–9. https://doi.org/10.1200/JCO.2010.32.2685.

———. 2012. “Adaptive Clinical Trials in Oncology.” Nature Reviews Clinical Oncology 9 (4): 199–207.

———. 2015. “The Brave New World of Clinical Cancer Research: Adaptive Biomarker-Driven Trials Integrating Clinical Practice with Clinical Research.” Molecular Oncology 9 (5): 951–59. https://doi.org/10.1016/j.molonc.2015.02.011.

———. 2025. “Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research.” Journal of Clinical Medicine 14 (15): 5267. https://doi.org/10.3390/jcm14155267.

Berry, Donald A., Shobha Dhadda, Michio Kanekiyo, Dayan Li, Chad J. Swanson, Michael Irizarry, Larry D. Kramer, and Scott M. Berry. 2023. “Lecanemab for Patients with Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.” JAMA Network Open 6 (4): e237230. https://doi.org/10.1001/jamanetworkopen.2023.7230.

Berry, Donald A., and Stephen G. Eick. 1995. “Adaptive Assignment Versus Balanced Randomization in Clinical Trials: A Decision Analysis.” Statistics in Medicine 14 (3): 231–46. https://doi.org/10.1002/sim.4780140302.

Berry, Donald A., and Bert Fristedt. 1985. Bandit Problems: Sequential Allocation of Experiments. London: Chapman; Hall. https://doi.org/10.1007/978-94-015-3711-7.

Berry, Donald A., and Chih-Hsiang Ho. 1988a. “One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision-Theoretic Approach.” Biometrics 44 (1): 219–27. https://doi.org/10.2307/2531909.

Berry, Donald A., and Chih-Hsiung Ho. 1988b. “One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision-Theoretic Approach.” Biometrics 44 (1): 219–27. https://doi.org/10.2307/2531909.

Berry, Donald A., and Yosef Hochberg. 1999. “Bayesian Perspectives on Multiple Comparisons.” Journal of Statistical Planning and Inference 82 (1–2): 215–27. https://doi.org/10.1016/s0378-3758(99)00044-0.

Berry, Donald A., Peter Müller, Andrew P. Grieve, Michael Smith, Thomas Parke, Robert Blazek, Neil Mitchard, and Martin Krams. 2002. “Adaptive Bayesian Designs for Dose-Ranging Drug Trials.” In Case Studies in Bayesian Statistics v, 162:99–181. Lecture Notes in Statistics. New York: Springer.

Berry, Lindsay R., Joe Marion, Scott M. Berry, and Kert Viele. 2024. “Optimal sample size division in two-stage seamless designs.” Pharmaceutical Statistics 23 (6): 854–63. https://doi.org/10.1002/pst.2394.

Berry, Scott M., and Donald A. Berry. 2004. “Accounting for Multiplicities in Assessing Drug Safety: A Three-Level Hierarchical Mixture Model.” Biometrics 60 (2): 418–26. https://doi.org/10.1111/j.0006-341X.2004.00186.x.

Berry, Scott M, Kristine R Broglio, Susan Groshen, and Donald A Berry. 2013. “Bayesian Hierarchical Modeling of Patient Subpopulations: Efficient Designs of Phase II Oncology Clinical Trials.” Clinical Trials 10 (5): 720–34. https://doi.org/10.1177/1740774513497539.

Berry, Scott M., Bradley P. Carlin, J. Jack Lee, and Peter Müller. 2010. Bayesian Adaptive Methods for Clinical Trials. Boca Raton: CRC Press.

Berry, Scott M., Jason T. Connor, and Roger J. Lewis. 2015. “The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments.” JAMA 313 (16): 1619–20. https://doi.org/10.1001/jama.2015.2316.

BIO, Informa Pharma Intelligence, and QLS Advisors. 2021. “Clinical Development Success Rates and Contributing Factors 2011–2020.” Biotechnology Innovation Organization. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf.

Blackwelder, William C. 1982. “‘Proving the Null Hypothesis’ in Clinical Trials.” Controlled Clinical Trials 3 (4): 345–53. https://doi.org/10.1016/0197-2456(82)90024-1.

Boag, J. W. 1949. “Maximum Likelihood Estimates of the Proportion of Patients Cured by Cancer Therapy.” Journal of the Royal Statistical Society: Series B 11 (1): 15–44. https://doi.org/10.1111/j.2517-6161.1949.tb00020.x.

Bombardier, Claire, Loren Laine, Alise Reicin, et al. 2000. “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis.” New England Journal of Medicine 343 (21): 1520–28. https://doi.org/10.1056/NEJM200011233432103.

Bresalier, Robert S., Robert S. Sandler, Hui Quan, et al. 2005. “Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial.” New England Journal of Medicine 352 (11): 1092–102. https://doi.org/10.1056/NEJMoa050493.

Breslow, N. 1974. “Covariance Analysis of Censored Survival Data.” Biometrics 30 (1): 89–99. https://doi.org/10.2307/2529620.

Bretz, Frank, Franz König, Werner Brannath, Ekkehard Glimm, and Martin Posch. 2009. “Adaptive Designs for Confirmatory Clinical Trials.” Statistics in Medicine 28 (8): 1181–1217. https://doi.org/10.1002/sim.3538.

Bretz, Frank, Willi Maurer, Werner Brannath, and Martin Posch. 2009. “A Graphical Approach to Sequentially Rejective Multiple Test Procedures.” Statistics in Medicine 28 (4): 586–604. https://doi.org/10.1002/sim.3495.

Bretz, Frank, Jose C. Pinheiro, and Michael Branson. 2005. “Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies.” Biometrics 61 (3): 738–48. https://doi.org/10.1111/j.1541-0420.2005.00344.x.

Bretz, Frank, Martin Posch, Ekkehard Glimm, Florian Klinglmueller, Willi Maurer, and Kornelius Rohmeyer. 2011. “Graphical Approaches for Multiple Comparison Procedures Using Weighted Bonferroni, Simes, or Parametric Tests.” Biometrical Journal 53 (6): 894–913. https://doi.org/10.1002/bimj.201000239.

Brockwell, Anthony E., and Joseph B. Kadane. 2003. “A Gridding Method for Bayesian Sequential Decision Problems.” Journal of Computational and Graphical Statistics 12 (3): 566–84.

Broglio, Kristine R., Jason T. Connor, and Scott M. Berry. 2014. “Not Too Big, Not Too Small: A Goldilocks Approach to Sample Size Selection.” Journal of Biopharmaceutical Statistics 24 (3): 685–705. https://doi.org/10.1080/10543406.2014.888569.

Broglio, Kristine, William J. Meurer, Valerie Durkalski, Qi Pauls, Jason Connor, Donald Berry, Roger J. Lewis, Karen C. Johnston, and William G. Barsan. 2022. “Comparison of Bayesian Vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.” JAMA Network Open 5 (5): e2211616. https://doi.org/10.1001/jamanetworkopen.2022.11616.

Brophy, James M. 2020. “Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization.” JAMA Internal Medicine 180: 986–92. https://doi.org/10.1001/jamainternmed.2020.1647.

Brophy, James M., and Lawrence Joseph. 1995. “Placing Trials in Context Using Bayesian Analysis: GUSTO Revisited by Reverend Bayes.” JAMA 273 (11): 871–75. https://doi.org/10.1001/jama.1995.03520350053028.

Brown, Barry W., Jay Herson, E. Neely Atkinson, and M. Elizabeth Rozell. 1987. “Projection from Previous Studies: A Bayesian and Frequentist Compromise.” Controlled Clinical Trials 8 (1): 29–44. https://doi.org/10.1016/0197-2456(87)90023-7.

Brunner, Hermine I, Carlos Abud-Mendoza, Diego O Viola, Inmaculada Calvo Penades, Deborah Levy, Jordi Anton, Julia E Calderon, et al. 2020. “Safety and Efficacy of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: Results from a Randomised, Placebo-Controlled Trial.” Annals of the Rheumatic Diseases 79 (10): 1340–48. https://doi.org/10.1136/annrheumdis-2020-217101.

Brutti, Pierpaolo, and Fulvio De Santis. 2008. “Robust Bayesian Sample Size Determination for Avoiding the Range of Equivalence in Clinical Trials.” Journal of Statistical Planning and Inference 138 (6): 1577–91. https://doi.org/10.1016/j.jspi.2007.05.041.

Burman, Carl-Fredrik, Christian Sonesson, and Olivier Guilbaud. 2009. “A Recycling Framework for the Construction of Bonferroni-Based Multiple Tests.” Statistics in Medicine 28 (5): 739–61. https://doi.org/10.1002/sim.3513.

Butler, Christopher C, F D Richard Hobbs, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, et al. 2023. “Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.” The Lancet 401 (10373): 281–93. https://doi.org/10.1016/S0140-6736(22)02597-1.

Campbell, Gregory. 2011. “Bayesian Statistics in Medical Devices: Innovation Sparked by the FDA.” Journal of Biopharmaceutical Statistics 21 (5): 871–87. https://doi.org/10.1080/10543406.2011.589638.

———. 2013. “Similarities and Differences of Bayesian Designs and Adaptive Designs for Medical Devices: A Regulatory View.” Statistics in Biopharmaceutical Research 5 (4): 356–68. https://doi.org/10.1080/19466315.2013.846873.

Campbell, Gregory, Telba Irony, Gene Pennello, and Laura Thompson. 2023. “Bayesian Statistics for Medical Devices: Progress Since 2010.” Therapeutic Innovation & Regulatory Science 57 (3): 453–63. https://doi.org/10.1007/s43441-022-00495-w.

Carlin, Bradley P., Joseph B. Kadane, and Alan E. Gelfand. 1998. “Approaches for Optimal Sequential Decision Analysis in Clinical Trials.” Biometrics 54: 964–75.

Chaloner, Kathryn, Timothy Church, Thomas A. Louis, and John P. Matts. 1993. “Graphical Elicitation of a Prior Distribution for a Clinical Trial.” Journal of the Royal Statistical Society, Series D (The Statistician) 42 (4): 341–53. https://doi.org/10.2307/2348469.

Chaloner, Kathryn, and Isabella Verdinelli. 1995. “Bayesian Experimental Design: A Review.” Statistical Science 10 (3): 273–304. https://doi.org/10.1214/ss/1177009939.

Chan, An-Wen, Isabelle Boutron, Sally Hopewell, David Moher, Kenneth F. Schulz, Gary S. Collins, et al. 2025. “SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomised Trials.” BMJ 389: e081477. https://doi.org/10.1136/bmj-2024-081477.

Chan, An-Wen, Jennifer M. Tetzlaff, Douglas G. Altman, Andreas Laupacis, Peter C. Gøtzsche, Karmela Krleža-Jerić, Asbjørn Hróbjartsson, et al. 2013. “SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials.” Annals of Internal Medicine 158 (3): 200–207. https://doi.org/10.7326/0003-4819-158-3-201302050-00583.

Chen, Ming-Hui, and Joseph G. Ibrahim. 2006. “The Relationship Between the Power Prior and Hierarchical Models.” Bayesian Analysis 1 (3): 551–74. https://doi.org/10.1214/06-BA118.

Chen, Ming-Hui, Joseph G. Ibrahim, and Debajyoti Sinha. 1999. “A New Bayesian Model for Survival Data with a Surviving Fraction.” Journal of the American Statistical Association 94 (447): 909–19. https://doi.org/10.1080/01621459.1999.10474196.

Chen, Wei-Chen, Chenguang Wang, Heng Li, Nelson Lu, Ram Tiwari, Yunling Xu, and Lilly Q. Yue. 2020. “Propensity Score-Integrated Composite Likelihood Approach for Augmenting the Control Arm of a Randomized Controlled Trial by Incorporating Real-World Data.” Journal of Biopharmaceutical Statistics 30 (3): 508–20. https://doi.org/10.1080/10543406.2020.1730877.

Chen, Yi-Hui J., David L. DeMets, and K. K. Gordon Lan. 2004. “Increasing the Sample Size When the Unblinded Interim Result Is Promising.” Statistics in Medicine 23 (7): 1023–38. https://doi.org/10.1002/sim.1688.

Cheng, Yi, and Yu Shen. 2005. “Bayesian Adaptive Designs for Clinical Trials.” Biometrika 92 (3): 633–46. https://doi.org/10.1093/biomet/92.3.633.

Cheung, Ying Kuen. 2011. Dose Finding by the Continual Reassessment Method. Boca Raton, FL: CRC Press. https://doi.org/10.1201/b10783.

Cheung, Ying Kuen, and Rick Chappell. 2000. “Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities.” Biometrics 56 (4): 1177–82. https://doi.org/10.1111/j.0006-341X.2000.01177.x.

Cho, Leslie, Stephen J. Nicholls, et al. 2026. “Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).” New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2610159.

Choodari-Oskooei, Babak, Daniel J. Bratton, Melissa R. Gannon, Angela M. Meade, Matthew R. Sydes, and Mahesh K. Parmar. 2020. “Adding New Experimental Arms to Randomised Clinical Trials: Impact on Error Rates.” Clinical Trials 17: 273–84. https://doi.org/10.1177/1740774520904346.

Chu, Yiyi, and Ying Yuan. 2018a. “A Bayesian Basket Trial Design Using a Calibrated Bayesian Hierarchical Model.” Clinical Trials 15 (2): 149–58. https://doi.org/10.1177/1740774518755122.

———. 2018b. “BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity.” Journal of the Royal Statistical Society: Series C 67 (3): 723–40. https://doi.org/10.1111/rssc.12255.

ClinicalTrials.gov. 2026a. “A Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients with Cardiovascular Disease (PREVAIL).” https://clinicaltrials.gov/study/NCT05202509.

———. 2026b. “A Donanemab Study in Participants with Preclinical Alzheimer’s Disease (TRAILBLAZER-ALZ 3).” https://clinicaltrials.gov/study/NCT05026866.

———. 2026c. “A Study of Retatrutide in Participants with Obesity and Cardiovascular Disease (TRIUMPH-3).” https://clinicaltrials.gov/study/NCT05882045.

———. 2026d. “A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults with Obesity (SURMOUNT-MMO).” https://clinicaltrials.gov/study/NCT05556512.

———. 2026e. “A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Participants with Elevated Lipoprotein(a) (ACCLAIM-Lp(a)).” https://clinicaltrials.gov/study/NCT06292013.

———. 2026f. “A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE).” ClinicalTrials.gov record NCT03970447. https://clinicaltrials.gov/study/NCT03970447.

———. 2026g. “AHEAD 3-45 Study: Efficacy and Safety of Treatment with Lecanemab in Participants with Preclinical Alzheimer’s Disease.” https://clinicaltrials.gov/study/NCT04468659.

———. 2026h. “Assessing the Impact of Lipoprotein(a) Lowering with Pelacarsen on Major Cardiovascular Events in Patients with CVD (Lp(a)HORIZON).” https://clinicaltrials.gov/study/NCT04023552.

———. 2026i. “Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) Outcomes Trial.” https://clinicaltrials.gov/study/NCT05581303.

———. 2026j. “REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living with Diseases in the Heart and Blood Vessels.” https://clinicaltrials.gov/study/NCT05669755.

———. 2026k. “Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND).” https://clinicaltrials.gov/study/NCT01394952.

Coalition, The Adaptive Platform Trials, Derek C. Angus, Brian M. Alexander, Scott Berry, Meredith Buxton, Roger Lewis, Melissa Paoloni, et al. 2019. “Adaptive platform trials: definition, design, conduct and reporting considerations.” Nature Reviews Drug Discovery 18 (10): 797–807. https://doi.org/10.1038/s41573-019-0034-3.

Collignon, Olivier, Christian Gartner, Anna-Bettina Haidich, Robert James Hemmings, Benjamin Hofner, et al. 2020. “Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials.” Clinical Pharmacology & Therapeutics 107: 1059–67. https://doi.org/10.1002/cpt.1804.

Colquhoun, David. 2014. “An Investigation of the False Discovery Rate and the Misinterpretation of p-Values.” Royal Society Open Science 1 (3): 140216. https://doi.org/10.1098/rsos.140216.

———. 2017. “The Reproducibility of Research and the Misinterpretation of p-Values.” Royal Society Open Science 4 (12): 171085. https://doi.org/10.1098/rsos.171085.

Colton, Theodore. 1963a. “A Model for Selecting One of Two Medical Treatments.” Journal of the American Statistical Association 58 (302): 388–400. https://doi.org/10.1080/01621459.1963.10500853.

———. 1963b. “A Model for Selecting One of Two Medical Treatments.” Journal of the American Statistical Association 58 (302): 388–400. https://doi.org/10.1080/01621459.1963.10500853.

Combes, Alain, David Hajage, Gilles Capellier, Alexandre Demoule, Sylvain Lavoué, Christophe Guervilly, Daniel Da Silva, et al. 2018. “Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.” New England Journal of Medicine 378 (21): 1965–75. https://doi.org/10.1056/NEJMoa1800385.

Cornfield, Jerome. 1966a. “A Bayesian Test of Some Classical Hypotheses, with Applications to Sequential Clinical Trials.” Journal of the American Statistical Association 61 (315): 577–94. https://doi.org/10.1080/01621459.1966.10480890.

———. 1966b. “Sequential Trials, Sequential Analysis and the Likelihood Principle.” The American Statistician 20 (2): 18–23. https://doi.org/10.1080/00031305.1966.10479786.

———. 1969. “The Bayesian Outlook and Its Application.” Biometrics 25 (4): 617–57. https://doi.org/10.2307/2528565.

Cornfield, Jerome, Max Halperin, and Samuel W. Greenhouse. 1969. “An Adaptive Procedure for Sequential Clinical Trials.” Journal of the American Statistical Association 64 (327): 759–70. https://doi.org/10.1080/01621459.1969.10501010.

Cox, D. R. 1958. Planning of Experiments. New York: John Wiley & Sons.

———. 1972. “Regression Models and Life-Tables.” Journal of the Royal Statistical Society: Series B (Methodological) 34 (2): 187–220. https://doi.org/10.1111/j.2517-6161.1972.tb00899.x.

———. 1975. “Partial Likelihood.” Biometrika 62 (2): 269–76. https://doi.org/10.1093/biomet/62.2.269.

Crisp, Adam, Sam Miller, Douglas Thompson, and Nicky Best. 2018. “Practical Experiences of Adopting Assurance as a Quantitative Framework to Support Decision Making in Drug Development.” Pharmaceutical Statistics 17 (4): 317–28. https://doi.org/10.1002/pst.1856.

Cui, Lu, H. M. James Hung, and Sue-Jane Wang. 1999. “Modification of Sample Size in Group Sequential Clinical Trials.” Biometrics 55 (3): 853–57. https://doi.org/10.1111/j.0006-341X.1999.00853.x.

Curfman, Gregory D., Stephen Morrissey, and Jeffrey M. Drazen. 2005. “Expression of Concern.” New England Journal of Medicine 353 (26): 2813–14. https://doi.org/10.1056/NEJMe058314.

Dallow, Nigel, Nicky Best, and Timothy H. Montague. 2018. “Better Decision Making in Drug Development Through Adoption of Formal Prior Elicitation.” Pharmaceutical Statistics 17 (4): 301–16. https://doi.org/10.1002/pst.1854.

Daniels, Cora. 2004. “The Man Who Changed Medicine.” Fortune, November. https://fortune.com/2013/03/03/the-man-who-changed-medicine-fortune-2004/.

Darling, D. A., and Herbert Robbins. 1967. “Confidence Sequences for Mean, Variance, and Median.” Proceedings of the National Academy of Sciences 58 (1): 66–68. https://doi.org/10.1073/pnas.58.1.66.

Dawid, A. P. 1982. “The Well-Calibrated Bayesian.” Journal of the American Statistical Association 77 (379): 605–10. https://doi.org/10.1080/01621459.1982.10477856.

de Finetti, Bruno. 1937. “Foresight: Its Logical Laws, Its Subjective Sources.” In Studies in Subjective Probability, edited by Henry E. Kyburg and Howard E. Smokler, 93–158. New York: Wiley.

De Santis, Fulvio. 2006. “Sample Size Determination for Robust Bayesian Analysis.” Journal of the American Statistical Association 101 (473): 278–91. https://doi.org/10.1198/016214505000000510.

Diamond, George A., and Sanjay Kaul. 2004. “Prior Convictions: Bayesian Approaches to the Analysis and Interpretation of Clinical Megatrials.” Journal of the American College of Cardiology 43 (11): 1929–39. https://doi.org/10.1016/j.jacc.2004.01.035.

Dimairo, Munyaradzi, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A Julious, Adrian P Mander, et al. 2020. “The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.” BMJ, m115. https://doi.org/10.1136/bmj.m115.

DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. 2016. “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.” Journal of Health Economics 47: 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012.

Dixon, W. J., and A. M. Mood. 1948. “A Method for Obtaining and Analyzing Sensitivity Data.” Journal of the American Statistical Association 43 (241): 109–26. https://doi.org/10.1080/01621459.1948.10483254.

Dmitrienko, Alex, and Ralph B. D’Agostino. 2013. “Traditional Multiplicity Adjustment Methods in Clinical Trials.” Statistics in Medicine 32 (29): 5172–5218. https://doi.org/10.1002/sim.5990.

Dmitrienko, Alex, Walter W. Offen, and Peter H. Westfall. 2003. “Gatekeeping Strategies for Clinical Trials That Do Not Require All Primary Effects to Be Significant.” Statistics in Medicine 22 (15): 2387–2400. https://doi.org/10.1002/sim.1526.

Dmitrienko, Alex, and Ming-Dauh Wang. 2006. “Bayesian Predictive Approach to Interim Monitoring in Clinical Trials.” Statistics in Medicine 25 (13): 2178–95. https://doi.org/10.1002/sim.2204.

Dodd, Lori E., Boris Freidlin, and Edward L. Korn. 2021. “Platform Trials , Beware the Noncomparable Control Group.” New England Journal of Medicine 384 (16): 1572–73. https://doi.org/10.1056/NEJMc2102446.

Duan, Yuyan, Keying Ye, and Eric P. Smith. 2006. “Evaluating Water Quality Using Power Priors to Incorporate Historical Information.” Environmetrics 17 (1): 95–106. https://doi.org/10.1002/env.752.

DuMouchel, William. 1999. “Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System.” The American Statistician 53 (3): 177–90. https://doi.org/10.1080/00031305.1999.10474456.

Dunn, Olive Jean. 1961. “Multiple Comparisons Among Means.” Journal of the American Statistical Association 56 (293): 52–64. https://doi.org/10.1080/01621459.1961.10482090.

Dunne, Julia, William J. Rodriguez, M. Dianne Murphy, B. Nhi Beasley, Gilbert J. Burckart, Jonca D. Filie, Lisa L. Lewis, et al. 2011. “Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs.” Pediatrics 128 (5): e1242–49. https://doi.org/10.1542/peds.2010-3487d.

Dunnett, Charles W. 1955. “A Multiple Comparison Procedure for Comparing Several Treatments with a Control.” Journal of the American Statistical Association 50 (272): 1096–1121. https://doi.org/10.1080/01621459.1955.10501294.

Dunnett, Charles W., and Marc Gent. 1977. “Significance Testing to Establish Equivalence Between Treatments, with Special Reference to Data in the Form of 2 x 2 Tables.” Biometrics 33 (4): 593–602. https://doi.org/10.2307/2529457.

Edwards, Ward, Harold Lindman, and Leonard J. Savage. 1963. “Bayesian Statistical Inference for Psychological Research.” Psychological Review 70 (3): 193–242.

Efron, Bradley. 1971. “Forcing a Sequential Experiment to Be Balanced.” Biometrika 58 (3): 403–17. https://doi.org/10.1093/biomet/58.3.403.

———. 2008. “Microarrays, Empirical Bayes and the Two-Groups Model.” Statistical Science 23 (1): 1–22. https://doi.org/10.1214/07-sts236.

Efron, Bradley, and Carl Morris. 1975. “Data Analysis Using Stein’s Estimator and Its Generalizations.” Journal of the American Statistical Association 70 (350): 311–19.

———. 1977. “Stein’s Paradox in Statistics.” Scientific American 236 (5): 119–27.

Eisele, Jeffrey R. 1994. “The Doubly Adaptive Biased Coin Design for Sequential Clinical Trials.” Journal of Statistical Planning and Inference 38 (2): 249–61. https://doi.org/10.1016/0378-3758(94)90038-8.

Eli Lilly and Company. 2022. “Form 10-k for the Fiscal Year Ended December 31, 2021.” https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/lly-20211231.htm.

———. 2026. “Lilly’s Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C.” https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html.

Ellenberg, Susan S., Thomas R. Fleming, and David L. DeMets. 2019. Data Monitoring Committees in Clinical Trials: A Practical Perspective. 2nd ed. Chichester: Wiley.

Emerson, Scott S., and Thomas R. Fleming. 1989. “Symmetric Group Sequential Test Designs.” Biometrics 45 (3): 905. https://doi.org/10.2307/2531692.

Emerson, Scott S., John M. Kittelson, and Daniel L. Gillen. 2007. “Frequentist Evaluation of Group Sequential Clinical Trial Designs.” Statistics in Medicine 26 (28): 5047–80. https://doi.org/10.1002/sim.2901.

European Commission and European Medicines Agency and Heads of Medicines Agencies. 2022. “Complex Clinical Trials: Questions and Answers.” https://health.ec.europa.eu/system/files/2022-06/medicinal_qa_complex_clinical-trials_en.pdf.

European Medicines Agency. 2014. “Assessment Report: Trulicity (Dulaglutide).” EMA/CHMP/524604/2014, Procedure No. EMEA/H/C/002825/0000. https://www.ema.europa.eu/en/documents/assessment-report/trulicity-epar-public-assessment-report_en.pdf.

———. 2017. “Guideline on Good Pharmacovigilance Practices (GVP) Module IX Addendum I: Methodological Aspects of Signal Detection from Spontaneous Reports of Suspected Adverse Reactions.” https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf.

———. 2026a. “Reflection Paper on Methodological Aspects in Confirmatory Platform Trials.” https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-aspects-confirmatory-platform-trials_en.pdf.

———. 2026b. “Concept Paper on the Development of a Reflection Paper on the Use of External Controls for Evidence Generation in Regulatory Decision-Making.” https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2007. “Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design (CHMP/EWP/2459/02).” European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf.

———. 2015. “Guideline on Adjustment for Baseline Covariates in Clinical Trials, EMA/CHMP/295050/2013.” https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adjustment-baseline-covariates-clinical-trials_en.pdf.

———. 2017. “Draft Guideline on Multiplicity Issues in Clinical Trials.” Draft for public consultation from 1 April to 30 June 2017, reference EMA/CHMP/44762/2017. https://www.ema.europa.eu/en/multiplicity-issues-clinical-trials-scientific-guideline.

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 2022. “Qualification Opinion for Prognostic Covariate Adjustment (PROCOVA).” European Medicines Agency. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf.

European Medicines Agency, Committee for Proprietary Medicinal Products. 2002. “Points to Consider on Multiplicity Issues in Clinical Trials (CPMP/EWP/908/99).” Adopted; legal effective date 1 April 2003. https://www.ema.europa.eu/en/multiplicity-issues-clinical-trials-scientific-guideline.

European Medicines Agency, Methodology Working Party. 2026. “Concept Paper for the Development of a Reflection Paper on the Use of Bayesian Methods in Clinical Development.” https://www.ema.europa.eu/system/files/documents/scientific-guideline/concept-paper-development-reflection-paper-use-bayesian-methods-en.pdf.

Evans, Scott R., Thomas R. Fleming, Holly Janes, and Lori E. Dodd. 2026. “Reflections on FDA Draft Guidance on Bayesian Methods in Trials: Protecting Scientific Integrity and Evidentiary Standards.” JAMA 335 (19): 1659. https://doi.org/10.1001/jama.2026.4175.

Evans, Stephen J. W., Patrick C. Waller, and Susan Davis. 2001. “Use of Proportional Reporting Ratios (PRRs) for Signal Generation from Spontaneous Adverse Drug Reaction Reports.” Pharmacoepidemiology and Drug Safety 10 (6): 483–86. https://doi.org/10.1002/pds.677.

Ewing, Charles M., Anna M. Ray, Ethan M. Lange, et al. 2012. “Germline Mutations in HOXB13 and Prostate-Cancer Risk.” New England Journal of Medicine 366 (2): 141–49. https://doi.org/10.1056/NEJMoa1110000.

Fayers, P. M., D. Ashby, and M. K. B. Parmar. 1997. “Tutorial in Biostatistics: Bayesian Data Monitoring in Clinical Trials.” Statistics in Medicine 16 (12): 1413–30. https://doi.org/10.1002/(sici)1097-0258(19970630)16:12<1413::aid-sim578>3.0.co;2-u.

Ferreira, David, Mael Barthoulot, Julien Pottecher, Klaus D. Torp, Pierre Diemunsch, and Nicolas Meyer. 2020. “A Consensus Checklist to Help Clinicians Interpret Clinical Trial Results Analysed by Bayesian Methods.” British Journal of Anaesthesia 125 (2): 208–15. https://doi.org/10.1016/j.bja.2020.04.093.

Fisher, Ronald A. 1935. The Design of Experiments. Edinburgh: Oliver; Boyd.

———. 1946. Statistical Methods for Research Workers. 10th ed. Edinburgh: Oliver; Boyd.

Fleming, Thomas R. 1982. “One-Sample Multiple Testing Procedure for Phase II Clinical Trials.” Biometrics 38 (1): 143–51. https://doi.org/10.2307/2530297.

———. 2008. “Current Issues in Non-Inferiority Trials.” Statistics in Medicine 27 (3): 317–32. https://doi.org/10.1002/sim.2855.

Fleming, Thomas R., and David P. Harrington. 1991. Counting Processes and Survival Analysis. New York: Wiley.

Flühler, Hans, Andrew P. Grieve, Daniel Mandallaz, Jochen Mau, and Barry Moser. 1983. “Bayesian Approach to Bioequivalence Assessment: An Example.” Journal of Pharmaceutical Sciences 72 (10): 1178–81. https://doi.org/10.1002/jps.2600721018.

Fourie Zirkelbach, Jeanne, Mirat Shah, Jonathon Vallejo, Joyce Cheng, Amal Ayyoub, Jiang Liu, et al. 2022. “Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.” Journal of Clinical Oncology 40 (30): 3489–3500. https://doi.org/10.1200/JCO.22.00371.

Freedman, L. S., D. Lowe, and P. Macaskill. 1984. “Stopping Rules for Clinical Trials Incorporating Clinical Opinion.” Biometrics 40 (3): 575–86. https://doi.org/10.2307/2530902.

Freedman, L. S., and D. J. Spiegelhalter. 1983. “The Assessment of Subjective Opinion and Its Use in Relation to Stopping Rules for Clinical Trials.” The Statistician 32 (1/2): 153–60. https://doi.org/10.2307/2987606.

Freedman, Laurence S. 1982. “Tables of the Number of Patients Required in Clinical Trials Using the Logrank Test.” Statistics in Medicine 1 (2): 121–29. https://doi.org/10.1002/sim.4780010204.

Freedman, Laurence S., and David J. Spiegelhalter. 1989. “Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials.” Controlled Clinical Trials 10 (4): 357–67. https://doi.org/10.1016/0197-2456(89)90001-9.

Freedman, Laurence S., David J. Spiegelhalter, and Mahesh K. B. Parmar. 1994. “The What, Why and How of Bayesian Clinical Trials Monitoring.” Statistics in Medicine 13 (13–14): 1371–83.

Freidlin, Boris, and Edward L. Korn. 2009. “Stopping Clinical Trials Early for Benefit: Impact on Estimation.” Clinical Trials 6 (2): 119–25. https://doi.org/10.1177/1740774509102310.

Galwey, Nicholas W. 2017. “Supplementation of a Clinical Trial by Historical Control Data: Is the Prospect of Dynamic Borrowing an Illusion?” Statistics in Medicine 36 (6): 899–916. https://doi.org/10.1002/sim.7180.

Gamalo‐Siebers, Margaret, Jasmina Savic, Cynthia Basu, Xin Zhao, Mathangi Gopalakrishnan, Aijun Gao, Guochen Song, et al. 2017. “Statistical Modeling for Bayesian Extrapolation of Adult Clinical Trial Information in Pediatric Drug Evaluation.” Pharmaceutical Statistics 16 (4): 232–49. https://doi.org/10.1002/pst.1807.

Gamble, Carrol, Ashma Krishan, Deborah Stocken, Steff Lewis, Edmund Juszczak, Caroline Doré, Paula R. Williamson, et al. 2017. “Guidelines for the Content of Statistical Analysis Plans in Clinical Trials.” JAMA 318 (23): 2337–43. https://doi.org/10.1001/jama.2017.18556.

Gao, Ping, James H. Ware, and Cyrus Mehta. 2008. “Sample Size Re-Estimation for Adaptive Sequential Design in Clinical Trials.” Journal of Biopharmaceutical Statistics 18 (6): 1184–96. https://doi.org/10.1080/10543400802369053.

Garrett-Mayer, Elizabeth. 2006. “The Continual Reassessment Method for Dose-Finding Studies: A Tutorial.” Clinical Trials 3 (1): 57–71. https://doi.org/10.1191/1740774506cn134oa.

Garthwaite, Paul H., Joseph B. Kadane, and Anthony O’Hagan. 2005. “Statistical Methods for Eliciting Probability Distributions.” Journal of the American Statistical Association 100 (470): 680–701. https://doi.org/10.1198/016214505000000105.

Gehan, Edmund A. 1961. “The Determination of the Number of Patients Required in a Preliminary and a Follow-up Trial of a New Chemotherapeutic Agent.” Journal of Chronic Diseases 13 (4): 346–53. https://doi.org/10.1016/0021-9681(61)90060-1.

Geiger, Michael J. et al. 2012. “An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics.” Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229681200600610.

Gelman, Andrew. 2006. “Prior Distributions for Variance Parameters in Hierarchical Models.” Bayesian Analysis 1 (3): 515–34. https://doi.org/10.1214/06-BA117A.

Gelman, Andrew, John B. Carlin, Hal S. Stern, David B. Dunson, Aki Vehtari, and Donald B. Rubin. 2013. Bayesian Data Analysis. 3rd ed. Chapman; Hall/CRC. https://doi.org/10.1201/b16018.

Gelman, Andrew, and Christian Hennig. 2017. “Beyond Subjective and Objective in Statistics.” Journal of the Royal Statistical Society: Series A 180 (4): 967–1033. https://doi.org/10.1111/rssa.12276.

Gelman, Andrew, Jennifer Hill, and Masanao Yajima. 2012. “Why We (Usually) Don’t Have to Worry about Multiple Comparisons.” Journal of Research on Educational Effectiveness 5 (2): 189–211. https://doi.org/10.1080/19345747.2011.618213.

Gelman, Andrew, Aleks Jakulin, Maria Grazia Pittau, and Yu-Sung Su. 2008. “A Weakly Informative Default Prior Distribution for Logistic and Other Regression Models.” The Annals of Applied Statistics 2 (4): 1360–83. https://doi.org/10.1214/08-AOAS191.

Gelman, Andrew, and Eric Loken. 2014. “The Statistical Crisis in Science.” American Scientist 102 (6): 460. https://doi.org/10.1511/2014.111.460.

Gelman, Andrew, and Francis Tuerlinckx. 2000. “Type S Error Rates for Classical and Bayesian Single and Multiple Comparison Procedures.” Computational Statistics 15 (3): 373–90. https://doi.org/10.1007/s001800000040.

Gelman, Andrew, Erik van Zwet, and Witold Więcek. 2026. “FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials.” JAMA 335 (19): 1662. https://doi.org/10.1001/jama.2026.4178.

Génin, Emmanuelle, Mark Martinez, and Françoise Clerget-Darpoux. 1995. “Posterior Probability of Linkage and Maximal Lod Score.” Annals of Human Genetics 59 (1): 123–32. https://doi.org/10.1111/j.1469-1809.1995.tb01610.x.

Gerstein, Hertzel C., Helen M. Colhoun, Gilles R. Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, et al. 2019. “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial.” The Lancet 394 (10193): 121–30. https://doi.org/10.1016/S0140-6736(19)31149-3.

Ghadessi, Mercedeh, Rui Tang, Joey Zhou, Rong Liu, Chenkun Wang, Kiichiro Toyoizumi, Chaoqun Mei, Lixia Zhang, C. Q. Deng, and Robert A. Beckman. 2020. “A Roadmap to Using Historical Controls in Clinical Trials by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG).” Orphanet Journal of Rare Diseases 15: 69. https://doi.org/10.1186/s13023-020-1332-x.

Gittins, J. C. 1979. “Bandit Processes and Dynamic Allocation Indices.” Journal of the Royal Statistical Society: Series B 41 (2): 148–77. https://doi.org/10.1111/j.2517-6161.1979.tb01068.x.

Gittins, J. C., and D. M. Jones. 1974. “A Dynamic Allocation Index for the Sequential Design of Experiments.” In Progress in Statistics, edited by J. Gani, 241–66. Amsterdam: North-Holland.

Gittins, John, and Hamid Pezeshk. 2000. “How Large Should a Clinical Trial Be?” Journal of the Royal Statistical Society, Series D (The Statistician) 49 (2): 177–87. https://doi.org/10.1111/1467-9884.00228.

Goligher, Ewan C., George Tomlinson, David Hajage, et al. 2018. “Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial.” JAMA 320 (21): 2251–59.

Goodman, Steven. 2008. “A Dirty Dozen: Twelve P-Value Misconceptions.” Seminars in Hematology 45 (3): 135–40. https://doi.org/10.1053/j.seminhematol.2008.04.003.

Goodman, Steven N. 1999a. “Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy.” Annals of Internal Medicine 130 (12): 995–1004. https://doi.org/10.7326/0003-4819-130-12-199906150-00008.

———. 1999b. “Toward Evidence-Based Medical Statistics. 2: The Bayes Factor.” Annals of Internal Medicine 130 (12): 1005–13. https://doi.org/10.7326/0003-4819-130-12-199906150-00019.

Goodman, Steven N., Marianna L. Zahurak, and Steven Piantadosi. 1995. “Some Practical Improvements in the Continual Reassessment Method for Phase I Studies.” Statistics in Medicine 14 (11): 1149–61. https://doi.org/10.1002/sim.4780141102.

Gosling, John Paul. 2018. “SHELF: The Sheffield Elicitation Framework.” In Elicitation: The Science and Art of Structuring Judgement, edited by Luis C. Dias, Alec Morton, and John Quigley, 61–93. Springer. https://doi.org/10.1007/978-3-319-65052-4_4.

Gould, A. Lawrence, and William B. Wang. 2017. “Monitoring Potential Adverse Event Rate Differences Using Data from Blinded Trials: The Canary in the Coal Mine.” Statistics in Medicine 36 (1): 92–104. https://doi.org/10.1002/sim.7129.

Greenland, Sander, Judea Pearl, and James M. Robins. 1999. “Confounding and Collapsibility in Causal Inference.” Statistical Science 14 (1): 29–46. https://doi.org/10.1214/ss/1009211805.

Grieve, Andrew P. 2016. “Idle Thoughts of a ‘Well-Calibrated’ Bayesian in Clinical Drug Development.” Pharmaceutical Statistics 15 (2): 96–108. https://doi.org/10.1002/pst.1736.

Grieve, Andrew P., and Michael Krams. 2005. “ASTIN: A Bayesian Adaptive Dose-Response Trial in Acute Stroke.” Clinical Trials 2 (4): 340–51. https://doi.org/10.1191/1740774505cn094oa.

Grooth, Harm-Jan de, and Olaf L. Cremer. 2024. “Bayes and the Evidence Base: Reanalyzing Trials Using Many Priors Does Not Contribute to Consensus.” American Journal of Respiratory and Critical Care Medicine 209 (5): 483–84. https://doi.org/10.1164/rccm.202308-1455VP.

Grossman, J., M. K. B. Parmar, D. J. Spiegelhalter, and L. S. Freedman. 1994. “A Unified Method for Monitoring and Analysing Controlled Trials.” Statistics in Medicine 13 (18): 1815–26. https://doi.org/10.1002/sim.4780131804.

Grundy, P. M., M. J. R. Healy, and D. H. Rees. 1956. “Economic Choice of the Amount of Experimentation.” Journal of the Royal Statistical Society, Series B 18 (1): 32–49. https://doi.org/10.1111/j.2517-6161.1956.tb00207.x.

Guo, Wentian, Sue-Jane Wang, Shengjie Yang, Henry Lynn, and Yuan Ji. 2017. “A Bayesian Interval Dose-Finding Design Addressing Ockham’s Razor: mTPI-2.” Contemporary Clinical Trials 58: 23–33. https://doi.org/10.1016/j.cct.2017.04.006.

GUSTO Investigators. 1993. “An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction.” New England Journal of Medicine 329: 673–82. https://doi.org/10.1056/NEJM199309023291001.

Halperin, Max, K. K. Gordon Lan, James H. Ware, Nancy J. Johnson, and David L. DeMets. 1982. “An Aid to Data Monitoring in Long-Term Clinical Trials.” Controlled Clinical Trials 3 (4): 311–23. https://doi.org/10.1016/0197-2456(82)90022-8.

Hanson, Timothy E., Adam J. Branscum, and Wesley O. Johnson. 2014. “Informative g-Priors for Logistic Regression.” Bayesian Analysis 9 (3): 597–612.

Harrell, Frank E., and Ya-Chen T. Shih. 2001. “Using Full Probability Models to Compute Probabilities of Actual Interest to Decision Makers.” International Journal of Technology Assessment in Health Care 17 (1): 17–26. https://doi.org/10.1017/S0266462301104034.

Harrington, David P., and Thomas R. Fleming. 1982. “A Class of Rank Test Procedures for Censored Survival Data.” Biometrika 69 (3): 553–66. https://doi.org/10.1093/biomet/69.3.553.

Hasselblad, Vic, and David F. Kong. 2001. “Statistical Methods for Comparison to Placebo in Active-Control Trials.” Drug Information Journal 35 (2): 435–49. https://doi.org/10.1177/009286150103500212.

Hatfield, Isabella, Annabel Allison, Laura Flight, Steven A. Julious, and Munyaradzi Dimairo. 2016. “Adaptive Designs Undertaken in Clinical Research: A Review of Registered Clinical Trials.” Trials 17: 150. https://doi.org/10.1186/s13063-016-1273-9.

Hauck, Walter W., and Sharon Anderson. 1984. “A New Statistical Procedure for Testing Equivalence in Two-Group Comparative Bioavailability Trials.” Journal of Pharmacokinetics and Biopharmaceutics 12 (1): 83–91. https://doi.org/10.1007/BF01063612.

Haybittle, J. L. 1971. “Repeated Assessment of Results in Clinical Trials of Cancer Treatment.” British Journal of Radiology 44 (526): 793–97. https://doi.org/10.1259/0007-1285-44-526-793.

Heitjan, Daniel F. 1997. “Bayesian Interim Analysis of Phase II Cancer Clinical Trials.” Statistics in Medicine 16 (16): 1791–1802. https://doi.org/10.1002/(SICI)1097-0258(19970830)16:16<1791::AID-SIM609>3.0.CO;2-E.

Hernán, Miguel A. 2010. “The Hazards of Hazard Ratios.” Epidemiology 21 (1): 13–15. https://doi.org/10.1097/EDE.0b013e3181c1ea43.

Hernández, Glenn, Gustavo A. Ospina-Tascón, Lucas P. Damiani, et al. 2019. “Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status Vs Serum Lactate Levels on 28-Day Mortality Among Patients with Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial.” JAMA 321 (7): 654–64. https://doi.org/10.1001/jama.2019.0071.

Herson, Jay. 1979. “Predictive Probability Early Termination Plans for Phase II Clinical Trials.” Biometrics 35 (4): 775–83. https://doi.org/10.2307/2530109.

Hey, Spencer Phillips, and Jonathan Kimmelman. 2015. “Are Outcome-Adaptive Allocation Trials Ethical?” Clinical Trials 12 (2): 102–6. https://doi.org/10.1177/1740774514563583.

Hill, A. Bradford. 1952. “The Clinical Trial.” New England Journal of Medicine 247 (4): 113–19. https://doi.org/10.1056/NEJM195207242470401.

Hill, Daniel N., Houssam Nassif, Yi Liu, Anand Iyer, and S. V. N. Vishwanathan. 2017. “An Efficient Bandit Algorithm for Realtime Multivariate Optimization.” In Proceedings of the 23rd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 1813–21. https://doi.org/10.1145/3097983.3098184.

Hill, Jennifer L. 2011. “Bayesian Nonparametric Modeling for Causal Inference.” Journal of Computational and Graphical Statistics 20 (1): 217–40. https://doi.org/10.1198/jcgs.2010.08162.

Hobbs, Brian P., Bradley P. Carlin, Sumithra J. Mandrekar, and Daniel J. Sargent. 2011. “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials.” Biometrics 67 (3): 1047–56. https://doi.org/10.1111/j.1541-0420.2011.01564.x.

Hobbs, Brian P., and Rodney Landin. 2018. “Bayesian Basket Trial Design with Exchangeability Monitoring.” Statistics in Medicine 37 (25): 3557–72. https://doi.org/10.1002/sim.7893.

Hobbs, Brian P., Daniel J. Sargent, and Bradley P. Carlin. 2012. “Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.” Bayesian Analysis 7 (3): 639–74. https://doi.org/10.1214/12-BA722.

Hochberg, Yosef. 1988. “A Sharper Bonferroni Procedure for Multiple Tests of Significance.” Biometrika 75 (4): 800–802. https://doi.org/10.1093/biomet/75.4.800.

Holford, Theodore R. 1976. “Life Tables with Concomitant Information.” Biometrics 32 (3): 587–97. https://doi.org/10.2307/2529747.

Holm, Sture. 1979. “A Simple Sequentially Rejective Multiple Test Procedure.” Scandinavian Journal of Statistics 6 (2): 65–70. https://www.jstor.org/stable/4615733.

Hommel, G. 1988. “A Stagewise Rejective Multiple Test Procedure Based on a Modified Bonferroni Test.” Biometrika 75 (2): 383–86. https://doi.org/10.1093/biomet/75.2.383.

Hopewell, Sally, An-Wen Chan, Gary S. Collins, Asbjørn Hróbjartsson, David Moher, Kenneth F. Schulz, Ruth Tunn, et al. 2025. “CONSORT 2025 Statement: Updated Guideline for Reporting Randomised Trials.” BMJ 389: e081123. https://doi.org/10.1136/bmj-2024-081123.

Horton, Bethany Jablonski, Nolan A. Wages, and Mark R. Conaway. 2017. “Performance of Toxicity Probability Interval Based Designs in Contrast to the Continual Reassessment Method.” Statistics in Medicine 36 (2): 291–300. https://doi.org/10.1002/sim.7043.

Houédé, Nadège, Peter F. Thall, Hoang Nguyen, Xavier Paoletti, and Andrew Kramar. 2010. “Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials.” Biometrics 66 (2): 532–40. https://doi.org/10.1111/j.1541-0420.2009.01302.x.

Hu, Feifang, and William F. Rosenberger. 2006. The Theory of Response-Adaptive Randomization in Clinical Trials. Hoboken, NJ: John Wiley & Sons. https://doi.org/10.1002/047005588X.

Hu, Feifang, and Li-Xin Zhang. 2004. “Asymptotic Properties of Doubly Adaptive Biased Coin Designs for Multitreatment Clinical Trials.” The Annals of Statistics 32 (1): 268–301. https://doi.org/10.1214/aos/1079120137.

Iasonos, Alexia, and John O’Quigley. 2014. “Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials.” Journal of Clinical Oncology 32 (23): 2505–11. https://doi.org/10.1200/jco.2013.54.6051.

Iasonos, Alexia, Andrew S. Wilton, Elyn R. Riedel, Venkatraman E. Seshan, and David R. Spriggs. 2008. “A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3+3 Dose Escalation Scheme in Phase I Dose-Finding Studies.” Clinical Trials 5 (5): 465–77. https://doi.org/10.1177/1740774508096474.

Ibrahim, Joseph G., and Ming-Hui Chen. 2000. “Power Prior Distributions for Regression Models.” Statistical Science 15 (1): 46–60.

Ibrahim, Joseph G., Ming-Hui Chen, Yeongjin Gwon, and Fang Chen. 2015. “The Power Prior: Theory and Applications.” Statistics in Medicine 34 (28): 3724–49.

Ibrahim, Joseph G., Ming-Hui Chen, and Debajyoti Sinha. 2001. Bayesian Survival Analysis. New York: Springer. https://doi.org/10.1007/978-1-4757-3447-8.

Inoue, Lurdes Y. T., Donald A. Berry, and Giovanni Parmigiani. 2005. “Relationship Between Bayesian and Frequentist Sample Size Determination.” The American Statistician 59 (1): 79–87. https://doi.org/10.1198/000313005X21069.

International Council for Harmonisation. 1994. “ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A.” https://database.ich.org/sites/default/files/E2A_Guideline.pdf.

———. 1995. “ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3.” https://database.ich.org/sites/default/files/E3_Guideline.pdf.

———. 1998. “ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9.” https://database.ich.org/sites/default/files/E9_Guideline.pdf.

———. 2000. “ICH E10: Choice of Control Group and Related Issues in Clinical Trials.” https://database.ich.org/sites/default/files/E10_Guideline.pdf.

———. 2016. “ICH M4: Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use.” https://www.ich.org/page/ctd.

———. 2019. “ICH E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.” https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.

———. 2021. “ICH E8(R1): General Considerations for Clinical Studies.” https://database.ich.org/sites/default/files/ICH_E8-R1_Guideline_Step4_2021_1006.pdf.

———. 2024. “ICH E11A: Pediatric Extrapolation.” https://database.ich.org/sites/default/files/ICH_E11A_Guideline_Step4_2024_0821.pdf.

———. 2025a. “E20 Adaptive Designs for Clinical Trials.” https://www.ema.europa.eu/en/ich-e20-adaptive-designs-clinical-trials-scientific-guideline.

———. 2025b. “ICH E6(R3): Guideline for Good Clinical Practice (GCP).” https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf.

———. 2025c. “ICH M11: Clinical Electronic Structured Harmonised Protocol (CeSHarP).” https://database.ich.org/sites/default/files/ICH_Step4_M11_Final_Guideline_2025_1119.pdf.

———. 2026a. “ICH M15: General Principles for Model-Informed Drug Development.” https://www.fda.gov/media/184747/download.

———. 2026b. “M15: General Principles for Model-Informed Drug Development.” https://www.fda.gov/media/184747/download.

Ioannidis, John P. A. 2005. “Why Most Published Research Findings Are False.” PLoS Medicine 2 (8): e124. https://doi.org/10.1371/journal.pmed.0020124.

Irwin, J. O. 1949. “The Standard Error of an Estimate of Expectation of Life, with Special Reference to Expectation of Tumourless Life in Experiments with Mice.” Journal of Hygiene 47 (2): 188–89. https://doi.org/10.1017/S0022172400014443.

Isakov, Leah, Andrew W. Lo, and Vahid Montazerhodjat. 2019. “Is the FDA Too Conservative or Too Aggressive?: A Bayesian Decision Analysis of Clinical Trial Design.” Journal of Econometrics 211 (1): 117–36. https://doi.org/10.1016/j.jeconom.2018.12.009.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1988. “Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17,187 Cases of Suspected Acute Myocardial Infarction: ISIS-2.” The Lancet 332 (8607): 349–60. https://doi.org/10.1016/S0140-6736(88)92833-4.

Ivanova, Anastasia, Bahjat F. Qaqish, and Michael J. Schell. 2005. “Continuous Toxicity Monitoring in Phase II Trials in Oncology.” Biometrics 61 (2): 540–45. https://doi.org/10.1111/j.1541-0420.2005.00311.x.

James, Nicholas D., Johann S. de Bono, Melissa R. Spears, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, Alastair W. S. Ritchie, et al. 2017. “Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.” New England Journal of Medicine 377 (4): 338–51. https://doi.org/10.1056/NEJMoa1702900.

James, Nicholas D, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, et al. 2016. “Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.” The Lancet 387 (10024): 1163–77. https://doi.org/10.1016/S0140-6736(15)01037-5.

James, W., and Charles Stein. 1961. “Estimation with Quadratic Loss.” In Proceedings of the Fourth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Contributions to the Theory of Statistics, 361–79. Berkeley, Calif.: University of California Press.

Jeffreys, Harold. 1935. “Some Tests of Significance, Treated by the Theory of Probability.” Mathematical Proceedings of the Cambridge Philosophical Society 31 (2): 203–22. https://doi.org/10.1017/S030500410001330X.

———. 1939. Theory of Probability. Oxford: Clarendon Press.

———. 1946. “An Invariant Form for the Prior Probability in Estimation Problems.” Proceedings of the Royal Society of London. Series A 186 (1007): 453–61. https://doi.org/10.1098/rspa.1946.0056.

———. 1998. Theory of Probability. Third Edition, Third Edition. Oxford Classic Texts in the Physical Sciences. Oxford, New York: Oxford University Press.

Jennison, Christopher, and Bruce W. Turnbull. 1984. “Repeated Confidence Intervals for Group Sequential Clinical Trials.” Controlled Clinical Trials 5 (1): 33–45. https://doi.org/10.1016/0197-2456(84)90148-X.

———. 2000. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC.

———. 2015. “Adaptive Sample Size Modification in Clinical Trials: Start Small Then Ask for More?” Statistics in Medicine 34 (29): 3793–3810. https://doi.org/10.1002/sim.6575.

Ji, Yuan, Yisheng Li, and B. Nebiyou Bekele. 2007. “Dose-Finding in Phase I Clinical Trials Based on Toxicity Probability Intervals.” Clinical Trials 4 (3): 235–44. https://doi.org/10.1177/1740774507079442.

Ji, Yuan, Ping Liu, Yisheng Li, and B. Nebiyou Bekele. 2010. “A Modified Toxicity Probability Interval Method for Dose-Finding Trials.” Clinical Trials 7 (6): 653–63. https://doi.org/10.1177/1740774510382799.

Jiang, Fei, J. Jack Lee, and Peter Müller. 2013. “A Bayesian Decision-Theoretic Sequential Response-Adaptive Randomization Design.” Statistics in Medicine 32 (12): 1975–94. https://doi.org/10.1002/sim.5735.

Jiang, Ziren, Chengxing (Cindy) Lu, Jialing Liu, Satrajit Roychoudhury, Daniel Meyer, Bo Huang, and Haitao Chu. 2023. “Nonconcurrent Controls in Platform Trials: Can We Borrow Their Concurrent Observation Data?” Statistics in Biopharmaceutical Research 17 (1): 17–26. https://doi.org/10.1080/19466315.2023.2267502.

Johns, Dan, and J. Scott Andersen. 1999. “Use of Predictive Probabilities in Phase II and Phase III Clinical Trials.” Journal of Biopharmaceutical Statistics 9 (1): 67–79. https://doi.org/10.1081/BIP-100101000.

Johnson, Valen E. 2013a. “Revised Standards for Statistical Evidence.” Proceedings of the National Academy of Sciences 110 (48): 19313–17. https://doi.org/10.1073/pnas.1313476110.

———. 2013b. “Uniformly Most Powerful Bayesian Tests.” The Annals of Statistics 41 (4): 1716–41. https://doi.org/10.1214/13-AOS1123.

Johnston, Karen C. et al. 2019. “Intensive Vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients with Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.” JAMA 322 (4): 326–35. https://doi.org/10.1001/jama.2019.9346.

Joseph, Lawrence, and Patrick Bélisle. 1997. “Bayesian Sample Size Determination for Normal Means and Differences Between Normal Means.” Journal of the Royal Statistical Society, Series D (The Statistician) 46 (2): 209–26. https://doi.org/10.1111/1467-9884.00077.

———. 2019. “Bayesian Consensus-Based Sample Size Criteria for Binomial Proportions.” Statistics in Medicine 38 (23): 4566–73. https://doi.org/10.1002/sim.8316.

Joseph, Lawrence, Patrick Bélisle, and Roxane du Berger. 2023. SampleSizeProportions: Calculating Sample Size Requirements When Estimating the Difference Between Two Binomial Proportions. https://CRAN.R-project.org/package=SampleSizeProportions.

Joseph, Lawrence, Roxane du Berger, and Patrick Bélisle. 1997. “Bayesian and Mixed Bayesian/Likelihood Criteria for Sample Size Determination.” Statistics in Medicine 16 (7): 769–81. https://doi.org/10.1002/(SICI)1097-0258(19970415)16:7<769::AID-SIM495>3.0.CO;2-V.

Joseph, Lawrence, David B. Wolfson, and Roxane du Berger. 1995. “Sample Size Calculations for Binomial Proportions via Highest Posterior Density Intervals.” The Statistician 44 (2): 143–54. https://doi.org/10.2307/2348439.

Jovin, Tudor G. et al. 2017. “Diffusion-Weighted Imaging or Computerized Tomography Perfusion Assessment with Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo (DAWN) Trial Methods.” International Journal of Stroke. https://doi.org/10.1177/1747493017710341.

Jüni, Peter, Linda Nartey, Stephan Reichenbach, Rebekka Sterchi, Paul A. Dieppe, and Matthias Egger. 2004. “Risk of Cardiovascular Events and Rofecoxib: Cumulative Meta-Analysis.” The Lancet 364 (9450): 2021–29. https://doi.org/10.1016/S0140-6736(04)17514-4.

Kadane, Joseph B., and Teddy Seidenfeld. 1990. “Randomization in a Bayesian Perspective.” Journal of Statistical Planning and Inference 25 (3): 329–45. https://doi.org/10.1016/0378-3758(90)90080-E.

Kahan, Brennan C., and Tim P. Morris. 2012. “Improper Analysis of Trials Randomised Using Stratified Blocks or Minimisation.” Statistics in Medicine 31 (4): 328–40. https://doi.org/10.1002/sim.4431.

Kaizer, Alexander M., Joseph S. Koopmeiners, and Brian P. Hobbs. 2018. “Bayesian Hierarchical Modeling Based on Multisource Exchangeability.” Biostatistics 19 (2): 169–84. https://doi.org/10.1093/biostatistics/kxx031.

Kalbfleisch, John D. 1978. “Non-Parametric Bayesian Analysis of Survival Time Data.” Journal of the Royal Statistical Society: Series B 40 (2): 214–21. https://doi.org/10.1111/j.2517-6161.1978.tb01666.x.

Kaplan, E. L., and Paul Meier. 1958. “Nonparametric Estimation from Incomplete Observations.” Journal of the American Statistical Association 53 (282): 457–81. https://doi.org/10.1080/01621459.1958.10501452.

Karrison, Theodore. 1987. “Restricted Mean Life with Adjustment for Covariates.” Journal of the American Statistical Association 82 (400): 1169–76. https://doi.org/10.1080/01621459.1987.10478555.

Kass, Robert E., and Joel B. Greenhouse. 1989a. “Comment on ‘Investigating Therapies of Potentially Great Benefit: ECMO’: A Bayesian Perspective.” Statistical Science 4 (4): 310–17. https://doi.org/10.1214/ss/1177012386.

———. 1989b. “Comment: A Bayesian Perspective.” Statistical Science 4 (4): 310–17.

Kass, Robert E., and Adrian E. Raftery. 1995. “Bayes Factors.” Journal of the American Statistical Association 90 (430): 773–95. https://doi.org/10.1080/01621459.1995.10476572.

Kass, Robert E., and Larry Wasserman. 1996. “The Selection of Prior Distributions by Formal Rules.” Journal of the American Statistical Association 91 (435): 1343–70. https://doi.org/10.1080/01621459.1996.10477003.

Kaufmann, Emilie, Nathaniel Korda, and Rémi Munos. 2012. “Thompson Sampling: An Asymptotically Optimal Finite-Time Analysis.” In Algorithmic Learning Theory, 199–213. https://doi.org/10.1007/978-3-642-34106-9_18.

Kernan, Walter N., Catherine M. Viscoli, Robert W. Makuch, Lawrence M. Brass, and Ralph I. Horwitz. 1999. “Stratified Randomization for Clinical Trials.” Journal of Clinical Epidemiology 52 (1): 19–26. https://doi.org/10.1016/S0895-4356(98)00138-3.

Kim, Edward S., Roy S. Herbst, Ignacio I. Wistuba, J. Jack Lee, George R. Blumenschein, Anne Tsao, David J. Stewart, et al. 2011. “The BATTLE Trial: Personalizing Therapy for Lung Cancer.” Cancer Discovery 1 (1): 44–53. https://doi.org/10.1158/2159-8274.CD-10-0010.

Kim, K., and David L. DeMets. 1987. “Design and Analysis of Group Sequential Tests Based on the Type I Error Spending Rate Function.” Biometrika 74 (1): 149–54. https://doi.org/10.1093/biomet/74.1.149.

Kittelson, John M., and Scott S. Emerson. 1999. “A Unifying Family of Group Sequential Test Designs.” Biometrics 55 (3): 874–82. https://doi.org/10.1111/j.0006-341x.1999.00874.x.

Kolmogorov, A. N. 1965. “Three Approaches to the Quantitative Definition of Information.” Problems of Information Transmission 1 (1): 1–7.

Kopp-Schneider, Annette, Silvia Calderazzo, and Manuel Wiesenfarth. 2020. “Power Gains by Using External Information in Clinical Trials Are Typically Not Possible When Requiring Strict Type I Error Control.” Biometrical Journal 62 (2): 361–74. https://doi.org/10.1002/bimj.201800395.

Korn, Edward L., and Boris Freidlin. 2011. “Outcome-Adaptive Randomization: Is It Useful?” Journal of Clinical Oncology 29 (6): 771–76. https://doi.org/10.1200/JCO.2010.31.1423.

Krams, Michael, Kennedy R. Lees, Werner Hacke, Andrew P. Grieve, Jean-Marc Orgogozo, and Gary A. Ford. 2003. “Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke.” Stroke 34 (11): 2543–48. https://doi.org/10.1161/01.STR.0000092527.33910.89.

Krotka, Pavla, Marta Bofill Roig, Katharina Hees, Peter Jacko, and Dominic Magirr. 2023. “NCC: Simulation and Analysis of Platform Trials with Non-Concurrent Controls.” https://doi.org/10.32614/CRAN.package.ncc.

Kruschke, John K. 2021. “Bayesian Analysis Reporting Guidelines.” Nature Human Behaviour 5 (10): 1282–91. https://doi.org/10.1038/s41562-021-01177-7.

Kulldorff, Martin, Robert L. Davis, Margarette Kolczak, Edwin Lewis, Tracy Lieu, and Richard Platt. 2011. “A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance.” Sequential Analysis 30 (1): 58–78. https://doi.org/10.1080/07474946.2011.539924.

Kunzmann, Kevin, Michael J. Grayling, Kim May Lee, David S. Robertson, Kaspar Rufibach, and James M. S. Wason. 2021. “A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials.” The American Statistician 75 (4): 424–32. https://doi.org/10.1080/00031305.2021.1901782.

Lachin, John M. 2005. “A Review of Methods for Futility Stopping Based on Conditional Power.” Statistics in Medicine 24 (18): 2747–64. https://doi.org/10.1002/sim.2151.

Lai, T. L., and Herbert Robbins. 1985. “Asymptotically Efficient Adaptive Allocation Rules.” Advances in Applied Mathematics 6 (1): 4–22. https://doi.org/10.1016/0196-8858(85)90002-8.

Lai, Tze Leung. 1976. “On Confidence Sequences.” The Annals of Statistics 4 (2): 265–80. https://doi.org/10.1214/aos/1176343406.

Lan, K. K. Gordon, and David L. DeMets. 1983. “Discrete Sequential Boundaries for Clinical Trials.” Biometrika 70 (3): 659–63.

Lan, K. K. Gordon, Richard Simon, and Max Halperin. 1982. “Stochastically Curtailed Tests in Long-Term Clinical Trials.” Communications in Statistics. Part C: Sequential Analysis 1 (3): 207–19. https://doi.org/10.1080/07474948208836014.

Lan, K. K. Gordon, and Janet Wittes. 1988. “The B-Value: A Tool for Monitoring Data.” Biometrics 44 (2): 579–85. https://doi.org/10.2307/2531870.

Le Tourneau, Christophe, J. Jack Lee, and Lillian L. Siu. 2009. “Dose Escalation Methods in Phase i Cancer Clinical Trials.” Journal of the National Cancer Institute 101 (10): 708–20. https://doi.org/10.1093/jnci/djp079.

Lee, J. Jack, Nan Chen, and Guosheng Yin. 2012. “Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization.” Clinical Cancer Research 18 (17): 4498–4507. https://doi.org/10.1158/1078-0432.CCR-11-2555.

Lee, J. Jack, and Caleb T. Chu. 2012. “Bayesian Clinical Trials in Action.” Statistics in Medicine 31 (25): 2955–72. https://doi.org/10.1002/sim.5404.

Lee, J. Jack, Frank E. Harrell, Lisa M. LaVange, and David J. Spiegelhalter. 2026. “Embracing Bayesian Methods in Clinical Trials.” JAMA 335 (19): 1664. https://doi.org/10.1001/jama.2026.4179.

Lee, J. Jack, and Diane D. Liu. 2008. “A Predictive Probability Design for Phase II Cancer Clinical Trials.” Clinical Trials 5 (2): 93–106. https://doi.org/10.1177/1740774508089279.

Lee, Kim May, and James Wason. 2020. “Including non-concurrent control patients in the analysis of platform trials: is it worth it?” BMC Medical Research Methodology 20 (1). https://doi.org/10.1186/s12874-020-01043-6.

Lee, Seung-Hwan. 2007. “On the Versatility of the Combination of the Weighted Log-Rank Statistics.” Computational Statistics & Data Analysis 51 (12): 6557–64. https://doi.org/10.1016/j.csda.2007.03.006.

Lehmacher, Walter, and Gernot Wassmer. 1999. “Adaptive Sample Size Calculations in Group Sequential Trials.” Biometrics 55 (4): 1286–90. https://doi.org/10.1111/j.0006-341X.1999.01286.x.

Lewis, Roger J., and Derek C. Angus. 2018. “Time for Clinicians to Embrace Their Inner Bayesian? Reanalysis of Results of a Clinical Trial of Extracorporeal Membrane Oxygenation.” JAMA 320 (21): 2208–10. https://doi.org/10.1001/jama.2018.16916.

Lewis, Roger J., and Donald A. Berry. 1994a. “Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic Designs.” Journal of the American Statistical Association 89 (428): 1528–34. https://doi.org/10.1080/01621459.1994.10476893.

———. 1994b. “Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic Designs.” Journal of the American Statistical Association 89 (428): 1528–34. https://doi.org/10.1080/01621459.1994.10476893.

Li, Ming, and Paul Vitányi. 2019. An Introduction to Kolmogorov Complexity and Its Applications. 4th ed. Springer. https://doi.org/10.1007/978-3-030-11298-1.

Lin, Junjing, Margaret Gamalo-Siebers, and Ram Tiwari. 2019. “Propensity-Score-Based Priors for Bayesian Augmented Control Design.” Pharmaceutical Statistics 18 (2): 223–38. https://doi.org/10.1002/pst.1918.

Lin, Ray S., Ji Lin, Satrajit Roychoudhury, Keaven M. Anderson, Tianle Hu, Bo Huang, Larry F. Leon, et al. 2020. “Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis.” Statistics in Biopharmaceutical Research 12 (2): 187–98. https://doi.org/10.1080/19466315.2019.1697738.

Lin, Ruitao, and Guosheng Yin. 2017. “Bayesian Optimal Interval Design for Dose Finding in Drug-Combination Trials.” Statistical Methods in Medical Research 26 (5): 2155–67. https://doi.org/10.1177/0962280215594494.

Lin, Ruitao, Yanhong Zhou, Fangrong Yan, Daniel Li, and Ying Yuan. 2020. “BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.” JCO Precision Oncology 4: 1393–1402. https://doi.org/10.1200/PO.20.00257.

Lin, Yong, and Weichung J. Shih. 2001. “Statistical Properties of the Traditional Algorithm-Based Designs for Phase I Cancer Clinical Trials.” Biostatistics 2 (2): 203–15. https://doi.org/10.1093/biostatistics/2.2.203.

Lincoff, A. Michael, Kirstine Brown-Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Soren Hardt-Lindberg, et al. 2023. “Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes.” New England Journal of Medicine 389 (24): 2221–32. https://doi.org/10.1056/NEJMoa2307563.

Lindley, D. V. 1957. “A Statistical Paradox.” Biometrika 44 (1/2): 187–92. https://doi.org/10.2307/2333251.

———. 1997. “The Choice of Sample Size.” Journal of the Royal Statistical Society, Series D (The Statistician) 46 (2): 129–38. https://doi.org/10.1111/1467-9884.00068.

Lindley, Dennis V. 1956. “On a Measure of the Information Provided by an Experiment.” Annals of Mathematical Statistics 27 (4): 986–1005. https://doi.org/10.1214/aoms/1177728069.

———. 1985. Making Decisions. 2nd ed. London: Wiley.

———. 1998. “Decision Analysis and Bioequivalence Trials.” Statistical Science 13 (2): 136–41. https://doi.org/10.1214/ss/1028905932.

Little, Roderick J. 2006. “Calibrated Bayes: A Bayes/Frequentist Roadmap.” The American Statistician 60 (3): 213–23. https://doi.org/10.1198/000313006X117837.

Liu, Suyu, and Ying Yuan. 2015. “Bayesian Optimal Interval Designs for Phase I Clinical Trials.” Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 (3): 507–23. https://doi.org/10.1111/rssc.12089.

Love, Sharon B. et al. 2017. “Embracing Model-Based Designs for Dose-Finding Trials.” British Journal of Cancer 117 (3): 332–39. https://doi.org/10.1038/bjc.2017.186.

Madigan, David, Patrick Ryan, Shawn Simpson, and Ivan Zorych. 2011. “Bayesian Methods in Pharmacovigilance.” In Bayesian Statistics 9, 421–38. Oxford University Press. https://doi.org/10.1093/acprof:oso/9780199694587.003.0014.

Magirr, Dominic, and Carl-Fredrik Burman. 2019. “Modestly Weighted Logrank Tests.” Statistics in Medicine 38 (20): 3782–90. https://doi.org/10.1002/sim.8186.

Magirr, Dominic, Thomas Jaki, and John Whitehead. 2012. “A Generalized Dunnett Test for Multi-Arm Multi-Stage Clinical Studies with Treatment Selection.” Biometrika 99 (2): 494–501. https://doi.org/10.1093/biomet/ass002.

Mandallaz, D., and J. Mau. 1981. “Comparison of Different Methods for Decision-Making in Bioequivalence Assessment.” Biometrics 37 (2): 213–22. https://doi.org/10.2307/2530412.

Mantel, Nathan. 1966. “Evaluation of Survival Data and Two New Rank Order Statistics Arising in Its Consideration.” Cancer Chemotherapy Reports 50 (3): 163–70.

Marcus, Ruth, Eric Peritz, and K. Ruben Gabriel. 1976. “On Closed Testing Procedures with Special Reference to Ordered Analysis of Variance.” Biometrika 63 (3): 655–60. https://doi.org/10.1093/biomet/63.3.655.

Marion, Joe, Elizabeth Lorenzi, Cora Allen-Savietta, Scott Berry, and Kert Viele. 2025. “Predictive Probabilities Made Simple: A Fast and Accurate Method for Clinical Trial Decision-Making.” Statistics in Medicine 44 (13–14): e70120. https://doi.org/10.1002/sim.70120.

Martin-Löf, Per. 1966. “The Definition of Random Sequences.” Information and Control 9 (6): 602–19. https://doi.org/10.1016/S0019-9958(66)80018-9.

Maurer, Willi, and Frank Bretz. 2013. “Multiple Testing in Group Sequential Trials Using Graphical Approaches.” Statistics in Biopharmaceutical Research 5 (4): 311–20. https://doi.org/10.1080/19466315.2013.807748.

Mayer, Cristiana, Inna Perevozskaya, Sergei Leonov, Vladimir Dragalin, et al. 2019. “Simulation Practices for Adaptive Trial Designs in Drug and Device Development.” Statistics in Biopharmaceutical Research 11 (4): 325–35. https://doi.org/10.1080/19466315.2018.1560359.

Medical Research Council Streptomycin in Tuberculosis Trials Committee. 1948. “Streptomycin Treatment of Pulmonary Tuberculosis.” British Medical Journal 2 (4582): 769–82. https://doi.org/10.1136/bmj.2.4582.769.

Medicines and Healthcare products Regulatory Agency. 2025. “MHRA Draft Guideline on the Use of External Control Arms Based on Real-World Data to Support Regulatory Decisions.” https://www.gov.uk/government/consultations/mhra-draft-guideline-on-the-use-of-external-control-arms-based-on-real-world-data-to-support-regulatory-decisions.

Mehrotra, Devan V., and Adeniyi J. Adewale. 2012. “Flagging Clinical Adverse Experiences: Reducing False Discoveries Without Materially Compromising Power for Detecting True Signals.” Statistics in Medicine 31 (18): 1918–30. https://doi.org/10.1002/sim.5310.

Mehta, Cyrus R., and Stuart J. Pocock. 2011. “Adaptive Increase in Sample Size When Interim Results Are Promising: A Practical Guide with Examples.” Statistics in Medicine 30 (28): 3267–84. https://doi.org/10.1002/sim.4102.

Meyer, Elias Laurin, Peter Mesenbrink, Cornelia Dunger-Baldauf, Hans-Jürgen Fülle, Ekkehard Glimm, Yuhan Li, Martin Posch, and Franz König. 2020. “The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.” Clinical Therapeutics 42 (7): 1330–60. https://doi.org/10.1016/j.clinthera.2020.05.010.

Meyer, Elias Laurin, Tobias Mielke, Marta Bofill Roig, Michaela Maria Freitag, Peter Jacko, et al. 2025. “Why and How Should We Simulate Platform Trials? Learnings from EU-PEARL.” BMC Medical Research Methodology 25. https://doi.org/10.1186/s12874-024-02453-6.

Montori, Victor M., P. J. Devereaux, Neill K. J. Adhikari, et al. 2005. “Randomized Trials Stopped Early for Benefit: A Systematic Review.” JAMA 294 (17): 2203–9. https://doi.org/10.1001/jama.294.17.2203.

Moore, A. D., and L. Joseph. 1999. “Sample Size Considerations for Superiority Trials in Systemic Lupus Erythematosus (SLE).” Lupus 8 (8): 612–19. https://doi.org/10.1191/096120399680411326.

Moore, Kelly L., and Mark J. van der Laan. 2009. “Covariate Adjustment in Randomized Trials with Binary Outcomes: Targeted Maximum Likelihood Estimation.” Statistics in Medicine 28 (1): 39–64. https://doi.org/10.1002/sim.3445.

Moore, Thomas J., James Heyward, Gerard Anderson, and G. Caleb Alexander. 2020. “Variation in the Estimated Costs of Pivotal Clinical Benefit Trials Supporting the US Approval of New Therapeutic Agents, 2015-2017: A Cross-Sectional Study.” BMJ Open 10: e038863. https://doi.org/10.1136/bmjopen-2020-038863.

Moore, Thomas J., Hanzhe Zhang, Gerard Anderson, and G. Caleb Alexander. 2018. “Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.” JAMA Internal Medicine 178 (11): 1451–57. https://doi.org/10.1001/jamainternmed.2018.3931.

Morita, Satoshi, Peter F. Thall, and Peter Müller. 2008. “Determining the Effective Sample Size of a Parametric Prior.” Biometrics 64 (2): 595–602.

———. 2010. “Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics.” Statistics in Biosciences 2 (1): 1–17. https://doi.org/10.1007/s12561-010-9018-x.

Morris, Tim P., Ian R. White, and Michael J. Crowther. 2019. “Using simulation studies to evaluate statistical methods.” Statistics in Medicine 38 (11): 2074–2102. https://doi.org/10.1002/sim.8086.

Morton, Newton E. 1955. “Sequential Tests for the Detection of Linkage.” American Journal of Human Genetics 7 (3): 277–318. https://pmc.ncbi.nlm.nih.gov/articles/PMC1716611/.

Müller, Hans-Helge, and Helmut Schäfer. 2001. “Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches.” Biometrics 57 (3): 886–91. https://doi.org/10.1111/j.0006-341X.2001.00886.x.

Müller, Peter, Donald A. Berry, Andrew P. Grieve, Michael Smith, and Michael Krams. 2007. “Simulation-Based Sequential Bayesian Design.” Journal of Statistical Planning and Inference 137 (10): 3140–50. https://doi.org/10.1016/j.jspi.2006.05.021.

Müller, Peter, and Giovanni Parmigiani. 1995. “Optimal Design via Curve Fitting of Monte Carlo Experiments.” Journal of the American Statistical Association 90 (432): 1322–30. https://doi.org/10.1080/01621459.1995.10476636.

Murray, Thomas A., Brian P. Hobbs, Theodore C. Lystig, and Bradley P. Carlin. 2014. “Semiparametric Bayesian Commensurate Survival Model for Post-Market Medical Device Surveillance with Non-Exchangeable Historical Data.” Biometrics 70: 185–91. https://doi.org/10.1111/biom.12115.

Muss, Hyman B., Donald A. Berry, Constance T. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, Lynn G. Dressler, Harvey J. Cohen, et al. 2009. “Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer.” New England Journal of Medicine 360 (20): 2055–65. https://doi.org/10.1056/NEJMoa0810266.

Nanda, Rita, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A. Jo Chien, et al. 2020. “Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer.” JAMA Oncology 6 (5): 676. https://doi.org/10.1001/jamaoncol.2019.6650.

Neuenschwander, Beat, Michael Branson, and Thomas Gsponer. 2008. “Critical Aspects of the Bayesian Approach to Phase I Cancer Trials.” Statistics in Medicine 27 (13): 2420–39. https://doi.org/10.1002/sim.3230.

Neuenschwander, Beat, Michael Branson, and David J. Spiegelhalter. 2009. “A Note on the Power Prior.” Statistics in Medicine 28 (28): 3562–66. https://doi.org/10.1002/sim.3722.

Neuenschwander, Beat, Gorana Capkun-Niggli, Michael Branson, and David J. Spiegelhalter. 2010. “Summarizing Historical Information on Controls in Clinical Trials.” Clinical Trials 7 (1): 5–18. https://doi.org/10.1177/1740774509356002.

Neuenschwander, Beat, Simon Wandel, Satrajit Roychoudhury, and Stuart Bailey. 2016. “Robust Exchangeability Designs for Early Phase Clinical Trials with Multiple Strata.” Pharmaceutical Statistics 15 (2): 123–34. https://doi.org/10.1002/pst.1730.

Neuhauser, Duncan. 2003. “Florence Nightingale Gets No Respect: As a Statistician That Is.” Quality and Safety in Health Care 12: 317. https://doi.org/10.1136/qhc.12.4.317.

Newcombe, Robert G. 1998. “Interval Estimation for the Difference Between Independent Proportions: Comparison of Eleven Methods.” Statistics in Medicine 17 (8): 873–90. https://doi.org/10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I.

Neyman, Jerzy, and Egon S. Pearson. 1933. “On the Problem of the Most Efficient Tests of Statistical Hypotheses.” Philosophical Transactions of the Royal Society of London. Series A 231: 289–337. https://doi.org/10.1098/rsta.1933.0009.

Nicholls, Stephen J., Imre Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, et al. 2025. “Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes.” New England Journal of Medicine 393 (24): 2409–20. https://doi.org/10.1056/NEJMoa2505928.

Nightingale, Florence. 1858. Notes on Matters Affecting the Health, Efficiency, and Hospital Administration of the British Army. London: Harrison; Sons.

Nogueira, Raul G., Ashutosh P. Jadhav, Diogo C. Haussen, Alain Bonafe, Ronald F. Budzik, Parita Bhuva, Dileep R. Yavagal, et al. 2018. “Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.” New England Journal of Medicine 378 (1): 11–21. https://doi.org/10.1056/NEJMoa1706442.

Novartis. 2026. “Novartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients with Elevated Lp(a) and Established Cardiovascular Disease.” https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd.

Novick, Melvin R., and James E. Grizzle. 1965. “A Bayesian Approach to the Analysis of Data from Clinical Trials.” Journal of the American Statistical Association 60 (309): 81–96.

Novo Nordisk A/S. 2025. “Annual Report 2024.” https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf.

O’Brien, Peter C., and Thomas R. Fleming. 1979. “A Multiple Testing Procedure for Clinical Trials.” Biometrics 35 (3): 549–56.

O’Hagan, Anthony, Caitlin E. Buck, Alireza Daneshkhah, J. Richard Eiser, Paul H. Garthwaite, David J. Jenkinson, Jeremy E. Oakley, and Tim Rakow. 2006. Uncertain Judgements: Eliciting Experts’ Probabilities. Chichester: Wiley. https://doi.org/10.1002/0470033312.

O’Hagan, Anthony, John W. Stevens, and Michael J. Campbell. 2005. “Assurance in Clinical Trial Design.” Pharmaceutical Statistics 4 (3): 187–201. https://doi.org/10.1002/pst.175.

O’Quigley, John, Margaret Pepe, and Lloyd Fisher. 1990. “Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer.” Biometrics 46 (1): 33–48. https://doi.org/10.2307/2531628.

O’Quigley, John, and Larry Z. Shen. 1996. “Continual Reassessment Method: A Likelihood Approach.” Biometrics 52 (2): 673–84. https://doi.org/10.2307/2532905.

O’Rourke, Patricia P., Robert K. Crone, Joseph P. Vacanti, James H. Ware, et al. 1989. “Extracorporeal Membrane Oxygenation and Conventional Medical Therapy in Neonates with Persistent Pulmonary Hypertension of the Newborn: A Prospective Randomized Study.” Pediatrics 84 (6): 957–63. https://doi.org/10.1542/peds.84.6.957.

Oakley, Jeremy E., and Anthony O’Hagan. 2019. “SHELF: The Sheffield Elicitation Framework.” School of Mathematics; Statistics, University of Sheffield. http://www.tonyohagan.co.uk/shelf/.

Pampallona, Sandro, and Anastasios A. Tsiatis. 1994. “Group Sequential Designs for One-Sided and Two-Sided Hypothesis Testing with Provision for Early Stopping in Favor of the Null Hypothesis.” Journal of Statistical Planning and Inference 42 (1–2): 19–35. https://doi.org/10.1016/0378-3758(94)90187-2.

Park, Jay J. H, Ellie Siden, Michael J. Zoratti, Louis Dron, Ofir Harari, Joel Singer, Richard T. Lester, Kristian Thorlund, and Edward J. Mills. 2019. “Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.” Trials 20 (1). https://doi.org/10.1186/s13063-019-3664-1.

Park, John W., Minetta C. Liu, Douglas Yee, Christina Yau, Laura J. van ’t Veer, W. Fraser Symmans, Melissa Paoloni, et al. 2016. “Adaptive Randomization of Neratinib in Early Breast Cancer.” New England Journal of Medicine 375 (1): 11–22. https://doi.org/10.1056/NEJMoa1513750.

Parmar, Mahesh K B, James Carpenter, and Matthew R Sydes. 2014. “More multiarm randomised trials of superiority are needed.” The Lancet 384 (9940): 283–84. https://doi.org/10.1016/S0140-6736(14)61122-3.

Parmar, Mahesh K. B., Gareth O. Griffiths, David J. Spiegelhalter, Robert L. Souhami, Douglas G. Altman, and Emile van der Scheuren. 2001. “Monitoring of Large Randomised Clinical Trials: A New Approach with Bayesian Methods.” The Lancet 358 (9279): 375–81. https://doi.org/10.1016/S0140-6736(01)05558-1.

Parmar, Mahesh K. B., David J. Spiegelhalter, Laurence S. Freedman, and CHART Steering Committee. 1994. “The CHART Trials: Bayesian Design and Monitoring in Practice.” Statistics in Medicine 13 (13–14): 1297–1312. https://doi.org/10.1002/sim.4780131304.

Parmar, Mahesh K. B., Matthew R. Sydes, Fay H. Cafferty, Babak Choodari-Oskooei, Ruth E. Langley, Louise Brown, Patrick P. J. Phillips, et al. 2017. “Testing Many Treatments Within a Single Protocol over 10 Years at MRC Clinical Trials Unit at UCL: Multi-Arm, Multi-Stage Platform, Umbrella and Basket Protocols.” Clinical Trials 14 (5): 451–61. https://doi.org/10.1177/1740774517725697.

Pennello, Gene, and Laura Thompson. 2008b. “Experience with Reviewing Bayesian Medical Device Trials.” Journal of Biopharmaceutical Statistics 18 (1): 81–115. https://doi.org/10.1080/10543400701668274.

———. 2008a. “Experience with Reviewing Bayesian Medical Device Trials.” Journal of Biopharmaceutical Statistics 18 (1): 81–115. https://doi.org/10.1080/10543400701668274.

Peto, Richard, and Julian Peto. 1972. “Asymptotically Efficient Rank Invariant Test Procedures.” Journal of the Royal Statistical Society: Series A 135 (2): 185–207. https://doi.org/10.2307/2344317.

Peto, R., M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, and P. G. Smith. 1976. “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient. I. Introduction and Design.” British Journal of Cancer 34 (6): 585–612. https://doi.org/10.1038/bjc.1976.220.

Pezeshk, Hamid. 2003. “Bayesian Techniques for Sample Size Determination in Clinical Trials: A Short Review.” Statistical Methods in Medical Research 12 (6): 489–504. https://doi.org/10.1191/0962280203sm345oa.

Pfizer Inc. 2022. “Protocol C4591001 (PF-07302048) Statistical Analysis Plan.” ClinicalTrials.gov NCT04368728, SAP_001, version 10. https://cdn.clinicaltrials.gov/large-docs/28/NCT04368728/SAP_001.pdf.

Pinheiro, José, Björn Bornkamp, Ekkehard Glimm, and Frank Bretz. 2014. “Model-Based Dose Finding Under Model Uncertainty Using General Parametric Models.” Statistics in Medicine 33 (10): 1646–61. https://doi.org/10.1002/sim.6052.

Pocock, Stuart J. 1976. “The Combination of Randomized and Historical Controls in Clinical Trials.” Journal of Chronic Diseases 29 (3): 175–88. https://doi.org/10.1016/0021-9681(76)90044-8.

———. 1977. “Group Sequential Methods in the Design and Analysis of Clinical Trials.” Biometrika 64 (2): 191–99.

Pocock, Stuart J., and Michael D. Hughes. 1989. “Practical Problems in Interim Analyses, with Particular Regard to Estimation.” Controlled Clinical Trials 10 (4, Supplement 1): 209S–221S. https://doi.org/10.1016/0197-2456(89)90059-7.

Pocock, Stuart J., and Richard Simon. 1975. “Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial.” Biometrics 31 (1): 103–15. https://doi.org/10.2307/2529712.

Polack, Fernando P., Stephen J. Thomas, Nicholas Kitchin, et al. 2020. “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.” New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2034577.

Polson, Nicholas G., and James Scott. 2018. AIQ: How People and Machines Are Smarter Together. St. Martin’s Press.

Polson, Nicholas G., and Vadim Sokolov. 2026a. “Bayesian Adaptive Clinical Trials: Priors, Thompson Sampling, Predictive Stopping and Backward Induction.”

———. 2026b. “Bayesian Versus Standard Clinical Trial Design: Theory, Evidence, and Protocol.”

———. 2026c. “E-Values on the Moderate Deviation Scale.”

———. 2026d. “Modal Doctor, Bayesian Patient.”

———. 2026e. “Sequential and Large-Scale Decision-Making in Clinical Trials: E-Values Versus Bayes Risk.”

Pottackal, Ginto, James Travis, Lei Nie, Rebecca Chiu, Rosemarie Neuner, Gregory Levin, Jing Niu, Anshu Marathe, Lily (Yeruk) Mulugeta, and Nikolay P. Nikolov. 2025. “Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States.” Lupus 34 (9): 943–52. https://doi.org/10.1177/09612033251349930.

Prentice, Ross L., Robert Langer, Marcia L. Stefanick, Barbara V. Howard, Mary Pettinger, Garnet Anderson, David Barad, et al. 2005. “Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy Between Observational Studies and the Women’s Health Initiative Clinical Trial.” American Journal of Epidemiology 162 (5): 404–14. https://doi.org/10.1093/aje/kwi223.

Proschan, Michael A., and Scott R. Evans. 2020. “Resist the Temptation of Response-Adaptive Randomization.” Clinical Infectious Diseases 71 (11): 3002–4. https://doi.org/10.1093/cid/ciaa334.

Proschan, Michael A., and Sally A. Hunsberger. 1995. “Designed Extension of Studies Based on Conditional Power.” Biometrics 51 (4): 1315. https://doi.org/10.2307/2533262.

Proschan, Michael A., K. K. Gordon Lan, and Janet Turk Wittes. 2006. Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer. https://doi.org/10.1007/978-0-387-44970-8.

Proschan, Michael A., and Myron A. Waclawiw. 2000. “Practical Guidelines for Multiplicity Adjustment in Clinical Trials.” Controlled Clinical Trials 21 (6): 527–39. https://doi.org/10.1016/s0197-2456(00)00106-9.

Prostate Cancer Foundation. 2025. “Our History.” https://pcf.org/about-pcf/our-history/.

Puijenbroek, Eugene P. van, Andrew Bate, Hubert G. M. Leufkens, Marie Lindquist, Roland Orre, and Antoine C. G. Egberts. 2002. “A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions.” Pharmacoepidemiology and Drug Safety 11 (1): 3–10. https://doi.org/10.1002/pds.668.

Quintana, Melanie, Benjamin R. Saville, Matteo Vestrucci, Michelle A. Detry, Lori Chibnik, Jeremy Shefner, James D. Berry, et al. 2023. “Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.” Annals of Neurology 94 (3): 547–60. https://doi.org/10.1002/ana.26714.

Quintana, Melanie, Kert Viele, and Roger J. Lewis. 2017. “Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials.” JAMA 318 (16): 1605–6. https://doi.org/10.1001/jama.2017.15574.

Racine, A., A. P. Grieve, H. Flühler, and A. F. M. Smith. 1986. “Bayesian Methods in Practice: Experiences in the Pharmaceutical Industry.” Journal of the Royal Statistical Society. Series C (Applied Statistics) 35 (2): 93–150.

Racine-Poon, A., A. P. Grieve, H. Flühler, and A. F. M. Smith. 1987. “A Two-Stage Procedure for Bioequivalence Studies.” Biometrics 43 (4): 847–56.

Raiffa, Howard, and Robert Schlaifer. 1961. Applied Statistical Decision Theory. Boston: Division of Research, Graduate School of Business Administration, Harvard University.

RECOVERY Collaborative Group, Peter Horby, Wei Shen Lim, Jonathan R. Emberson, Marion Mafham, Jennifer L. Bell, et al. 2021. “Dexamethasone in Hospitalized Patients with Covid-19.” New England Journal of Medicine 384 (8): 693–704. https://doi.org/10.1056/NEJMoa2021436.

Reiner, Eric, Xavier Paoletti, and John O’Quigley. 1999. “Operating Characteristics of the Standard Phase I Clinical Trial Design.” Computational Statistics & Data Analysis 30 (3): 303–15. https://doi.org/10.1016/S0167-9473(98)00095-4.

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Ewan C. Goligher, Corrinne A. Bradbury, Bryan J. McVerry, et al. 2021. “Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.” New England Journal of Medicine 385 (9): 777–89. https://doi.org/10.1056/NEJMoa2103417.

REMAP-CAP Investigators, Anthony C. Gordon, Paul R. Mouncey, Farah Al-Beidh, Kathryn M. Rowan, Alistair D. Nichol, et al. 2021. “Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.” New England Journal of Medicine 384 (16): 1491–1502. https://doi.org/10.1056/NEJMoa2100433.

Ritchie, Craig W., José Luis Molinuevo, Luc Truyen, Andrew Satlin, Serge Van der Geyten, Simon Lovestone, and EPAD Consortium. 2016. “Development of Interventions for the Secondary Prevention of Alzheimer’s Dementia: The European Prevention of Alzheimer’s Dementia (EPAD) Project.” Lancet Psychiatry 3 (2): 179–86. https://doi.org/10.1016/S2215-0366(15)00454-X.

Robbins, Herbert. 1952. “Some Aspects of the Sequential Design of Experiments.” Bulletin of the American Mathematical Society 58 (5): 527–35. https://doi.org/10.1090/S0002-9904-1952-09620-8.

———. 1970. “Statistical Methods Related to the Law of the Iterated Logarithm.” The Annals of Mathematical Statistics 41 (5): 1397–1409. https://doi.org/10.1214/aoms/1177696786.

Robertson, David S., Kim May Lee, Boryana C. López-Kolkovska, and Sofía S. Villar. 2023. “Response-Adaptive Randomization in Clinical Trials: From Myths to Practical Considerations.” Statistical Science 38 (2): 185–208. https://doi.org/10.1214/22-STS865.

Robertson, David S., James M. S. Wason, Franz König, Martin Posch, and Thomas Jaki. 2023. “Online Error Rate Control for Platform Trials.” Statistics in Medicine 42 (14): 2475–95. https://doi.org/10.1002/sim.9733.

Rodda, Bruce E., and Richard L. Davis. 1980. “Determining the Probability of an Important Difference in Bioavailability.” Clinical Pharmacology & Therapeutics 28 (2): 247–52. https://doi.org/10.1038/clpt.1980.157.

Rogatko, André et al. 2007. “Translation of Innovative Designs into Phase I Trials.” Journal of Clinical Oncology 25 (31): 4982–86. https://doi.org/10.1200/JCO.2007.12.1012.

Roig, Marta Bofill, Cora Burgwinkel, Ursula Garczarek, Franz Koenig, Martin Posch, Quynh Nguyen, and Katharina Hees. 2023. “On the use of non-concurrent controls in platform trials: a scoping review.” Trials 24 (1). https://doi.org/10.1186/s13063-023-07398-7.

Roig, Marta Bofill, Pavla Krotka, Carl-Fredrik Burman, Ekkehard Glimm, Stefan M. Gold, Katharina Hees, Peter Jacko, et al. 2022. “On model-based time trend adjustments in platform trials with non-concurrent controls.” BMC Medical Research Methodology 22 (1). https://doi.org/10.1186/s12874-022-01683-w.

Rosenberger, William F., and John M. Lachin. 1993. “The Use of Response-Adaptive Designs in Clinical Trials.” Controlled Clinical Trials 14 (6): 471–84. https://doi.org/10.1016/0197-2456(93)90028-C.

———. 2016. Randomization in Clinical Trials: Theory and Practice. 2nd ed. Hoboken, NJ: John Wiley & Sons.

Rosenberger, William F., Nigel Stallard, Anastasia Ivanova, Cherice N. Harper, and Michelle L. Ricks. 2001. “Optimal Adaptive Designs for Binary Response Trials.” Biometrics 57 (3): 909–13. https://doi.org/10.1111/j.0006-341X.2001.00909.x.

Rosenblum, Michael, and Mark J. van der Laan. 2010. “Simple, Efficient Estimators of Treatment Effects in Randomized Trials Using Generalized Linear Models to Leverage Baseline Variables.” The International Journal of Biostatistics 6 (1). https://doi.org/10.2202/1557-4679.1138.

Rosner, Gary L., and Donald A. Berry. 1995. “A Bayesian Group Sequential Design for a Multiple Arm Randomized Clinical Trial.” Statistics in Medicine 14 (4): 381–94. https://doi.org/10.1002/sim.4780140405.

Ross, Jessica L., Arman Sabbaghi, Run Zhuang, and Daniele Bertolini. 2024. “Enhancing Longitudinal Clinical Trial Efficiency with Digital Twins and Prognostic Covariate-Adjusted Mixed Models for Repeated Measures (PROCOVA-MMRM).” arXiv Preprint arXiv:2404.17576. https://arxiv.org/abs/2404.17576.

Rossouw, Jacques E., Garnet L. Anderson, Ross L. Prentice, Andrea Z. LaCroix, Charles Kooperberg, Marcia L. Stefanick, Rebecca D. Jackson, et al. 2002. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (3): 321–33. https://doi.org/10.1001/jama.288.3.321.

Rothman, Kenneth J. 1990. “No Adjustments Are Needed for Multiple Comparisons.” Epidemiology 1 (1): 43–46. https://doi.org/10.1097/00001648-199001000-00010.

Rothman, Kenneth J., Stephan Lanes, and Susan T. Sacks. 2004. “The Reporting Odds Ratio and Its Advantages over the Proportional Reporting Ratio.” Pharmacoepidemiology and Drug Safety 13 (8): 519–23. https://doi.org/10.1002/pds.1001.

Rothmann, Mark, Ning Li, Gang Chen, George Y. H. Chi, Robert Temple, and Hsiao‐Hui Tsou. 2003. “Design and Analysis of Non-Inferiority Mortality Trials in Oncology.” Statistics in Medicine 22 (2): 239–64. https://doi.org/10.1002/sim.1400.

Röver, Christian, and Tim Friede. 2020. “Dynamically Borrowing Strength from Another Study Through Shrinkage Estimation.” Statistical Methods in Medical Research 29: 293–308. https://doi.org/10.1177/0962280219833079.

Royall, Richard M. 1991. “Ethics and Statistics in Randomized Clinical Trials.” Statistical Science 6 (1): 52–62. https://doi.org/10.1214/ss/1177011934.

Roychoudhury, Satrajit, Keaven M. Anderson, Jiabu Ye, and Pralay Mukhopadhyay. 2021. “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance from a Cross-Pharma Working Group.” Statistics in Biopharmaceutical Research 15 (2): 280–94. https://doi.org/10.1080/19466315.2021.1874507.

Royston, Patrick, Friederike M.-S. Barthel, Mahesh K. B. Parmar, Babak Choodari-Oskooei, and Valerie Isham. 2011. “Designs for Clinical Trials with Time-to-Event Outcomes Based on Stopping Guidelines for Lack of Benefit.” Trials 12: 81. https://doi.org/10.1186/1745-6215-12-81.

Royston, Patrick, and Mahesh K. B. Parmar. 2011. “The Use of Restricted Mean Survival Time to Estimate the Treatment Effect in Randomized Clinical Trials When the Proportional Hazards Assumption Is in Doubt.” Statistics in Medicine 30 (19): 2409–21. https://doi.org/10.1002/sim.4274.

———. 2013. “Restricted Mean Survival Time: An Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials with a Time-to-Event Outcome.” BMC Medical Research Methodology 13: 152. https://doi.org/10.1186/1471-2288-13-152.

Royston, Patrick, Mahesh K. B. Parmar, and Wendi Qian. 2003. “Novel Designs for Multi-Arm Clinical Trials with Survival Outcomes with an Application in Ovarian Cancer.” Statistics in Medicine 22 (14): 2239–56. https://doi.org/10.1002/sim.1430.

Ruberg, Stephen J., Francois Beckers, Rob Hemmings, Peter Honig, Telba Irony, Lisa LaVange, Grazyna Lieberman, et al. 2023. “Application of Bayesian Approaches in Drug Development: Starting a Virtuous Cycle.” Nature Reviews Drug Discovery 22 (3): 235–50. https://doi.org/10.1038/s41573-023-00638-0.

Rubin, Donald B. 1974. “Estimating Causal Effects of Treatments in Randomized and Nonrandomized Studies.” Journal of Educational Psychology 66 (5): 688–701. https://doi.org/10.1037/h0037350.

———. 1978. “Bayesian Inference for Causal Effects: The Role of Randomization.” The Annals of Statistics 6 (1): 34–58. https://doi.org/10.1214/aos/1176344064.

———. 1984. “Bayesianly Justifiable and Relevant Frequency Calculations for the Applied Statistician.” The Annals of Statistics 12 (4): 1151–72. https://doi.org/10.1214/aos/1176346785.

Rufibach, Kaspar, Hans Ulrich Burger, and Markus Abt. 2016. “Bayesian Predictive Power: Choice of Prior and Some Recommendations for Its Use as Probability of Success in Drug Development.” Pharmaceutical Statistics 15 (5): 438–46. https://doi.org/10.1002/pst.1764.

Russo, Daniel, and Benjamin Van Roy. 2016. “An Information-Theoretic Analysis of Thompson Sampling.” Journal of Machine Learning Research 17 (68): 1–30. https://arxiv.org/abs/1403.5341.

Ryan, Donna H., Ildiko Lingvay, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Steven E. Kahn, Robert F. Kushner, et al. 2020. “Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) Rationale and Design.” American Heart Journal 229: 61–69. https://doi.org/10.1016/j.ahj.2020.07.008.

Ryan, Elizabeth G., Emma M. Harrison, Rupert M. Pearse, and Simon Gates. 2019. “Perioperative Haemodynamic Therapy for Major Gastrointestinal Surgery: The Effect of a Bayesian Approach to Interpreting the Findings of a Randomised Controlled Trial.” BMJ Open 9 (3): e024256. https://doi.org/10.1136/bmjopen-2018-024256.

Sacks, Henry, Thomas C. Chalmers, and Harry Smith. 1982. “Randomized Versus Historical Controls for Clinical Trials.” American Journal of Medicine 72 (2): 233–40. https://doi.org/10.1016/0002-9343(82)90815-4.

Sahu, Sujit K., and Thomas M. F. Smith. 2006. “A Bayesian Method of Sample Size Determination with Practical Applications.” Journal of the Royal Statistical Society, Series A 169 (2): 235–53. https://doi.org/10.1111/j.1467-985x.2006.00408.x.

Sattar, Naveed, Hertzel C. Gerstein, David D’Alessio, et al. 2026. “Estimating the True MACE Benefits from Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.” Diabetes Care. https://doi.org/10.2337/dc26-0298.

Saunders, Stina, Sarah Gregory, Matthew H. S. Clement, Cindy Birck, Serge Van Der Geyten, and Craig W. Ritchie. 2022. “The European Prevention of Alzheimer’s Dementia Programme: An Innovative Medicines Initiative-Funded Partnership to Facilitate Secondary Prevention of Alzheimer’s Disease Dementia.” Frontiers in Neurology 13: 1051543. https://doi.org/10.3389/fneur.2022.1051543.

Savage, Leonard J. 1954. The Foundations of Statistics. Wiley.

Saville, Benjamin R., Donald A. Berry, Nicholas S. Berry, Kert Viele, and Scott M. Berry. 2022. “The Bayesian Time Machine: Accounting for Temporal Drift in Multi-Arm Platform Trials.” Clinical Trials 19 (5): 490–501. https://doi.org/10.1177/17407745221112013.

Saville, Benjamin R, and Scott M Berry. 2016. “Efficiencies of Platform Clinical Trials: A Vision of the Future.” Clinical Trials 13 (3): 358–66. https://doi.org/10.1177/1740774515626362.

Saville, Benjamin R., Jason T. Connor, Gregory D. Ayers, and JoAnn Alvarez. 2014. “The Utility of Bayesian Predictive Probabilities for Interim Monitoring of Clinical Trials.” Clinical Trials 11 (4): 485–93. https://doi.org/10.1177/1740774514531352.

Schmidli, Heinz, Sandro Gsteiger, Satrajit Roychoudhury, Anthony O’Hagan, David Spiegelhalter, and Beat Neuenschwander. 2014. “Robust Meta-Analytic-Predictive Priors in Clinical Trials with Historical Control Information.” Biometrics 70 (4): 1023–32. https://doi.org/10.1111/biom.12242.

Schmidli, Heinz, Simon Wandel, and Beat Neuenschwander. 2013. “The Network Meta-Analytic-Predictive Approach to Non-Inferiority Trials.” Statistical Methods in Medical Research 22: 219–40. https://doi.org/10.1177/0962280211432512.

Schoenfeld, David. 1981. “The Asymptotic Properties of Nonparametric Tests for Comparing Survival Distributions.” Biometrika 68 (1): 316–19. https://doi.org/10.1093/biomet/68.1.316.

Schoenfeld, David A. 1983. “Sample-Size Formula for the Proportional-Hazards Regression Model.” Biometrics 39 (2): 499–503. https://doi.org/10.2307/2531021.

Schuirmann, Donald J. 1987. “A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability.” Journal of Pharmacokinetics and Biopharmaceutics 15 (6): 657–80. https://doi.org/10.1007/BF01068419.

Schulz, Kenneth F. 1995. “Subverting Randomization in Controlled Trials.” JAMA 274 (18): 1456–58. https://doi.org/10.1001/jama.1995.03530180050029.

Schulz, Kenneth F., Iain Chalmers, Richard J. Hayes, and Douglas G. Altman. 1995. “Empirical Evidence of Bias: Dimensions of Methodological Quality Associated with Estimates of Treatment Effects in Controlled Trials.” JAMA 273 (5): 408–12. https://doi.org/10.1001/jama.1995.03520290060030.

Schwarz, Gideon. 1978. “Estimating the Dimension of a Model.” The Annals of Statistics 6 (2): 461–64. https://doi.org/10.1214/aos/1176344136.

Scott, James G., and James O. Berger. 2006. “An Exploration of Aspects of Bayesian Multiple Testing.” Journal of Statistical Planning and Inference 136 (7): 2144–62. https://doi.org/10.1016/j.jspi.2005.08.031.

———. 2010. “Bayes and Empirical-Bayes Multiplicity Adjustment in the Variable-Selection Problem.” The Annals of Statistics 38 (5): 2587–2619. https://doi.org/10.1214/10-aos792.

Scott, Neil W., Gladys C. McPherson, Craig R. Ramsay, and Marion K. Campbell. 2002. “The Method of Minimization for Allocation to Clinical Trials: A Review.” Controlled Clinical Trials 23 (6): 662–74. https://doi.org/10.1016/S0197-2456(02)00242-8.

Sellke, Thomas, M. J Bayarri, and James O Berger. 2001. “Calibration of ρ Values for Testing Precise Null Hypotheses.” The American Statistician 55 (1): 62–71.

Selwyn, M. R., A. P. Dempster, and N. R. Hall. 1981. “A Bayesian Approach to Bioequivalence for the 2 x 2 Changeover Design.” Biometrics 37 (1): 11–21. https://doi.org/10.2307/2530518.

Senn, Stephen. 1994. “Testing for Baseline Balance in Clinical Trials.” Statistics in Medicine 13 (17): 1715–26. https://doi.org/10.1002/sim.4780131703.

———. 2006. “Change from Baseline and Analysis of Covariance Revisited.” Statistics in Medicine 25 (24): 4334–44. https://doi.org/10.1002/sim.2682.

———. 2013. “Seven Myths of Randomisation in Clinical Trials.” Statistics in Medicine 32 (9): 1439–50. https://doi.org/10.1002/sim.5713.

Sertkaya, Aylin, Hui-Hsing Wong, Amber Jessup, and Trinidad Beleche. 2016. “Key Cost Drivers of Pharmaceutical Clinical Trials in the United States.” Clinical Trials 13 (2): 117–26. https://doi.org/10.1177/1740774515625964.

Shafer, Glenn. 2021. “Testing by Betting: A Strategy for Statistical and Scientific Communication.” Journal of the Royal Statistical Society: Series A 184 (2): 407–31. https://doi.org/10.1111/rssa.12647.

Shafer, Glenn, Alexander Shen, Nikolai Vereshchagin, and Vladimir Vovk. 2011. “Test Martingales, Bayes Factors and p-Values.” Statistical Science 26 (1): 84–101. https://doi.org/10.1214/10-sts347.

Shafer, Glenn, and Vladimir Vovk. 2019. Game-Theoretic Foundations for Probability and Finance. Hoboken, NJ: Wiley. https://doi.org/10.1002/9781118548035.

Shah, Mirat, Atiqur Rahman, Marc R. Theoret, and Richard Pazdur. 2021. “The Drug-Dosing Conundrum in Oncology: When Less Is More.” New England Journal of Medicine 385 (16): 1445–47. https://doi.org/10.1056/NEJMp2109826.

Sheiner, Lewis B. 1997. “Learning Versus Confirming in Clinical Drug Development.” Clinical Pharmacology & Therapeutics 61 (3): 275–91. https://doi.org/10.1016/S0009-9236(97)90160-0.

Silva, Rebecca, Christina Yap, Richard Carvajal, and Shing M. Lee. 2021. “Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.” JCO Precision Oncology 5: 1024–34. https://doi.org/10.1200/PO.21.00136.

Simes, R. J. 1986. “An Improved Bonferroni Procedure for Multiple Tests of Significance.” Biometrika 73 (3): 751–54. https://doi.org/10.1093/biomet/73.3.751.

Simon, Richard. 1989. “Optimal Two-Stage Designs for Phase II Clinical Trials.” Controlled Clinical Trials 10 (1): 1–10. https://doi.org/10.1016/0197-2456(89)90015-9.

———. 1999. “Bayesian Design and Analysis of Active Control Clinical Trials.” Biometrics 55 (2): 484–87. https://doi.org/10.1111/j.0006-341X.1999.00484.x.

Simon, Richard, Boris Freidlin, Lawrence Rubinstein, Susan G. Arbuck, Jerry Collins, and Michaele C. Christian. 1997. “Accelerated Titration Designs for Phase I Clinical Trials in Oncology.” Journal of the National Cancer Institute 89 (15): 1138–47. https://doi.org/10.1093/jnci/89.15.1138.

Simon, Richard, Susan Geyer, Janakiraman Subramanian, and Sameek Roychowdhury. 2016. “The Bayesian Basket Design for Genomic Variant-Driven Phase II Trials.” Seminars in Oncology 43 (1): 13–18. https://doi.org/10.1053/j.seminoncol.2016.01.002.

Simpson, Daniel, Håvard Rue, Andrea Riebler, Thiago G. Martins, and Sigrunn H. Sørbye. 2017. “Penalising Model Component Complexity: A Principled, Practical Approach to Constructing Priors.” Statistical Science 32 (1): 1–28. https://doi.org/10.1214/16-STS576.

Sims, John R., Jennifer A. Zimmer, Cynthia D. Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, et al. 2023. “Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.” JAMA 330 (6): 512–27. https://doi.org/10.1001/jama.2023.13239.

Skene, A. M., and J. C. Wakefield. 1990. “Hierarchical Models for Multi-Centre Binary Response Studies.” Statistics in Medicine 9: 919–29.

Skoulidis, Ferdinandos et al. 2021. “Sotorasib for Lung Cancers with KRAS p.G12C Mutation.” New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2103695.

Skrivanek, Zachary et al. 2014. “Dose-Finding Results in an Adaptive, Seamless, Randomized Trial of Once-Weekly Dulaglutide Combined with Metformin in Type 2 Diabetes Patients (AWARD-5).” Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12305.

Smith, Jeffrey R., Diha Freije, John D. Carpten, et al. 1996. “Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search.” Science 274 (5291): 1371–74. https://doi.org/10.1126/science.274.5291.1371.

Smith, Zachary P., Joseph A. DiMasi, and Kenneth A. Getz. 2024. “New Estimates on the Cost of a Delay Day in Drug Development.” Therapeutic Innovation & Regulatory Science 58 (5): 855–62. https://doi.org/10.1007/s43441-024-00667-w.

Snapinn, Steven, and Qi Jiang. 2008. “Preservation of Effect and the Regulatory Approval of New Treatments on the Basis of Non-Inferiority Trials.” Statistics in Medicine 27 (3): 382–91. https://doi.org/10.1002/sim.3073.

Sokolova, Alexandra O., and Vadim Sokolov. 2026. “E-Values for Adaptive Clinical Trials: Anytime-Valid Monitoring in Practice.” arXiv Preprint arXiv:2602.06379.

Sokolova, Alexandra, Vadim Sokolov, and Nicholas G. Polson. 2026a. “Some Bayesian Perspectives on Clinical Trials.” arXiv Preprint arXiv:2602.09208.

———. 2026b. “Three Hundred Families in Three Weeks: A Bayesian Analysis of the 1995 Larry King Appeal and the Value of the Information It Bought.”

Sorić, Branko. 1989. “Statistical ‘Discoveries’ and Effect-Size Estimation.” Journal of the American Statistical Association 84 (406): 608–10. https://doi.org/10.1080/01621459.1989.10478811.

Spiegelhalter, David J., Keith R. Abrams, and Jonathan P. Myles. 2004. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: Wiley. https://doi.org/10.1002/0470092602.

Spiegelhalter, David J., and Laurence S. Freedman. 1986. “A Predictive Approach to Selecting the Size of a Clinical Trial, Based on Subjective Clinical Opinion.” Statistics in Medicine 5 (1): 1–13. https://doi.org/10.1002/sim.4780050103.

Spiegelhalter, David J., Laurence S. Freedman, and Patricia R. Blackburn. 1986. “Monitoring Clinical Trials: Conditional or Predictive Power?” Controlled Clinical Trials 7 (1): 8–17. https://doi.org/10.1016/0197-2456(86)90003-6.

Spiegelhalter, David J., Laurence S. Freedman, and Mahesh K. B. Parmar. 1994. “Bayesian Approaches to Randomized Trials.” Journal of the Royal Statistical Society, Series A 157 (3): 357–416. https://doi.org/10.2307/2983527.

Spiegelhalter, David J., Jonathan P. Myles, David R. Jones, and Keith R. Abrams. 2000. “Bayesian Methods in Health Technology Assessment: A Review.” Health Technology Assessment 4 (38). https://doi.org/10.3310/hta4380.

Stallard, Nigel, and Susan Todd. 2003. “Sequential Designs for Phase III Clinical Trials Incorporating Treatment Selection.” Statistics in Medicine 22 (5): 689–703. https://doi.org/10.1002/sim.1362.

Stein, Charles. 1956. “Inadmissibility of the Usual Estimator for the Mean of a Multivariate Normal Distribution.” In Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability, 1:197–206. https://www.degruyter.com/document/doi/10.1525/9780520313880-018/html.

Sterne, Jonathan A. C., and George Davey Smith. 2001. “Sifting the Evidence: What’s Wrong with Significance Tests?” BMJ 322 (7280): 226–31. https://doi.org/10.1136/bmj.322.7280.226.

Stone, Gregg W., Joseph F. Sabik, Patrick W. Serruys, et al. 2016. “Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.” New England Journal of Medicine 375: 2223–35. https://doi.org/10.1056/NEJMoa1610227.

Storer, Barry E. 1989. “Design and Analysis of Phase I Clinical Trials.” Biometrics 45 (3): 925–37. https://doi.org/10.2307/2531693.

Struebing, Alessandria, Chelsea McKibbon, Haoyao Ruan, Emma Mackay, Natalie Dennis, Russanthy Velummailum, Philip He, et al. 2024. “Augmenting External Control Arms Using Bayesian Borrowing: A Case Study in First-Line Non-Small Cell Lung Cancer.” Journal of Comparative Effectiveness Research 13 (5). https://doi.org/10.57264/cer-2023-0175.

Struthers, Cynthia A., and John D. Kalbfleisch. 1986. “Misspecified Proportional Hazard Models.” Biometrika 73 (2): 363–69. https://doi.org/10.1093/biomet/73.2.363.

Stryker Neurovascular. 2017. “DAWN Trial Statistical Analysis Plan, CDM10000704 Rev AB.” ClinicalTrials.gov NCT02142283, SAP_001. https://cdn.clinicaltrials.gov/large-docs/83/NCT02142283/SAP_001.pdf.

Sung, Lillian, Jill Hayden, Mark L. Greenberg, Gideon Koren, Brian M. Feldman, and George A. Tomlinson. 2005. “Seven Items Were Identified for Inclusion When Reporting a Bayesian Analysis of a Clinical Study.” Journal of Clinical Epidemiology 58 (3): 261–68. https://doi.org/10.1016/j.jclinepi.2004.08.010.

Suntharalingam, Ganesh, Meghan R. Perry, Stephen Ward, et al. 2006. “Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412.” New England Journal of Medicine 355 (10): 1018–28. https://doi.org/10.1056/NEJMoa063842.

Swanson, Chad J., Yong Zhang, Shobha Dhadda, Jianing Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, et al. 2021. “A Randomized, Double-Blind, Phase 2b Proof-of-Concept Clinical Trial in Early Alzheimer’s Disease with Lecanemab, an Anti-aβ Protofibril Antibody.” Alzheimer’s Research and Therapy 13 (1): 80. https://doi.org/10.1186/s13195-021-00813-8.

Sydes, Matthew R., Mahesh K. B. Parmar, Nicholas D. James, Noel W. Clarke, David P. Dearnaley, Malcolm D. Mason, Rachel C. Morgan, Karen Sanders, and Patrick Royston. 2009. “Issues in Applying Multi-Arm Multi-Stage Methodology to a Clinical Trial in Prostate Cancer: The MRC STAMPEDE Trial.” Trials 10: 39. https://doi.org/10.1186/1745-6215-10-39.

Szarfman, Ana, Stella G. Machado, and Robert T. O’Neill. 2002. “Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database.” Drug Safety 25 (6): 381–92. https://doi.org/10.2165/00002018-200225060-00001.

Tan, Say-Beng, and David Machin. 2002. “Bayesian Two-Stage Designs for Phase II Clinical Trials.” Statistics in Medicine 21 (14): 1991–2012. https://doi.org/10.1002/sim.1176.

Taves, Donald R. 1974. “Minimization: A New Method of Assigning Patients to Treatment and Control Groups.” Clinical Pharmacology & Therapeutics 15 (5): 443–53. https://doi.org/10.1002/cpt1974155443.

Thall, Peter F. 2024. Bayesian Precision Medicine. Boca Raton, FL: Chapman; Hall/CRC.

Thall, Peter F., and John D. Cook. 2004. “Dose-Finding Based on Efficacy-Toxicity Trade-Offs.” Biometrics 60 (3): 684–93.

Thall, Peter F., Richard C. Herrick, Hoang Q. Nguyen, Julia L. Venier, and James C. Norris. 2015. “Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes.” Journal of Biopharmaceutical Statistics 25 (6): 1257–75. https://doi.org/10.1080/10543406.2014.920873.

Thall, Peter F., and Kenneth E. Russell. 1998. “A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials.” Biometrics 54 (1): 251–64.

Thall, Peter F., and Richard Simon. 1994. “Practical Bayesian Guidelines for Phase IIB Clinical Trials.” Biometrics 50 (2): 337–49. https://doi.org/10.2307/2533377.

Thall, Peter F., Richard M. Simon, and Elihu H. Estey. 1995. “Bayesian Sequential Monitoring Designs for Single-Arm Clinical Trials with Multiple Outcomes.” Statistics in Medicine 14 (4): 357–79. https://doi.org/10.1002/sim.4780140404.

———. 1996. “New Statistical Strategy for Monitoring Safety and Efficacy in Single-Arm Clinical Trials.” Journal of Clinical Oncology 14 (1): 296–303. https://doi.org/10.1200/jco.1996.14.1.296.

Thall, Peter F., Richard Simon, and Susan S. Ellenberg. 1988. “Two-Stage Selection and Testing Designs for Comparative Clinical Trials.” Biometrika 75 (2): 303–10. https://doi.org/10.1093/biomet/75.2.303.

Thall, Peter F., and J. Kyle Wathen. 2007. “Practical Bayesian Adaptive Randomisation in Clinical Trials.” European Journal of Cancer 43 (5): 859–66.

Thall, Peter F., J. Kyle Wathen, B. Nebiyou Bekele, Richard E. Champlin, Laurence H. Baker, and Robert S. Benjamin. 2003. “Hierarchical Bayesian Approaches to Phase II Trials in Diseases with Multiple Subtypes.” Statistics in Medicine 22 (5): 763–80. https://doi.org/10.1002/sim.1399.

Thall, P., P. Fox, and J. Wathen. 2015. “Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.” Annals of Oncology 26 (8): 1621–28. https://doi.org/10.1093/annonc/mdv238.

Thompson, William R. 1933. “On the Likelihood That One Unknown Probability Exceeds Another in View of the Evidence of Two Samples.” Biometrika 25 (3/4): 285–94.

Trinquart, Ludovic, Justine Jacot, Sarah C. Conner, and Raphaël Porcher. 2016. “Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.” Journal of Clinical Oncology 34 (15): 1813–19. https://doi.org/10.1200/JCO.2015.64.2488.

Trippa, Lorenzo, Eudocia Q. Lee, Patrick Y. Wen, Tracy T. Batchelor, Timothy Cloughesy, Giovanni Parmigiani, and Brian M. Alexander. 2012. “Bayesian Adaptive Randomized Trial Design for Patients with Recurrent Glioblastoma.” Journal of Clinical Oncology 30 (26): 3258–63. https://doi.org/10.1200/JCO.2011.39.8420.

Tsiatis, Anastasios A., Marie Davidian, Min Zhang, and Xiaomin Lu. 2008. “Covariate Adjustment for Two-Sample Treatment Comparisons in Randomized Clinical Trials: A Principled yet Flexible Approach.” Statistics in Medicine 27 (23): 4658–77. https://doi.org/10.1002/sim.3113.

Tsiatis, Anastasios A., and Cyrus Mehta. 2003. “On the Inefficiency of the Adaptive Design for Monitoring Clinical Trials.” Biometrika 90 (2): 367–78. https://doi.org/10.1093/biomet/90.2.367.

UK Collaborative ECMO Trial Group. 1996. “UK Collaborative Randomised Trial of Neonatal Extracorporeal Membrane Oxygenation.” The Lancet 348 (9020): 75–82. https://doi.org/10.1016/S0140-6736(96)04100-1.

United States Congress. 1962. “Federal Food, Drug, and Cosmetic Act, Section 505(d) (21 u.s.c. 355(d)): Grounds for Refusing to Approve an Application.” https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec355.htm.

———. 1997. “Food and Drug Administration Modernization Act of 1997.”

———. 2016. “21st Century Cures Act.” https://www.congress.gov/bill/114th-congress/house-bill/34.

University of Washington. 1999. “Seattle Researchers Zero in on Location of Gene for Inherited Prostate Cancer; Gene Also Linked to Brain Cancer, News Release, 9 March 1999.” https://www.washington.edu/news/1999/03/09/seattle-researchers-zero-in-on-location-of-gene-for-inherited-prostate-cancer-gene-also-linked-to-brain-cancer/.

Uno, Hajime, Brian Claggett, Lu Tian, Eisuke Inoue, Paul Gallo, Toshio Miyata, Deborah Schrag, et al. 2014. “Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis.” Journal of Clinical Oncology 32 (22): 2380–85. https://doi.org/10.1200/jco.2014.55.2208.

U.S. Congress. 2022. “Food and Drug Omnibus Reform Act (FDORA) of 2022.” https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-omnibus-reform-act-fdora-2022.

U.S. Food and Drug Administration. 1994. “Dose-Response Information to Support Drug Registration.” U.S. Food and Drug Administration. https://www.fda.gov/media/71279/download.

———. 2006. “Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees.” https://www.fda.gov/media/75398/download.

———. 2008. “Guidance for Industry. Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes.” Center for Drug Evaluation and Research. https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic.

———. 2010. “Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials.” U.S. Food and Drug Administration. https://www.fda.gov/media/71512/download.

———. 2014. “Expedited Programs for Serious Conditions – Drugs and Biologics: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.

———. 2016. “Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry.” https://www.fda.gov/media/78504/download.

———. 2018a. “Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry.” Final guidance, December 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics.

———. 2018b. “Special Protocol Assessment: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/special-protocol-assessment-guidance-industry.

———. 2019a. “Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.

———. 2019b. “Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.” https://www.fda.gov/media/78495/download.

———. 2019c. “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.” U.S. Food and Drug Administration. https://www.fda.gov/media/133660/download.

———. 2020a. “Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry.” U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products.

———. 2020b. “Supplement Approval Letter, BLA 125469/s-033, Trulicity (Dulaglutide).” https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125469Orig1s033ltr.pdf.

———. 2021a. “Emergency Use Authorization Letter, Pfizer-BioNTech COVID-19 Vaccine (Reissued 10 May 2021; Original EUA 11 December 2020).” https://www.fda.gov/media/144412/download.

———. 2021b. “FDA Approves First COVID-19 Vaccine.” Press announcement, 23 August 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

———. 2021c. “PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027.” https://www.fda.gov/media/151712/download.

———. 2021d. “Project Optimus: Reforming the Dose Optimization and Dose Selection Paradigm in Oncology.” FDA Oncology Center of Excellence. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus.

———. 2022a. “Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics.” U.S. Food and Drug Administration. https://www.fda.gov/media/120721/download.

———. 2022b. “Multiple Endpoints in Clinical Trials: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials-guidance-industry.

———. 2023a. “Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products.

———. 2023b. “Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug.

———. 2023c. “Rare Diseases: Considerations for the Development of Drugs and Biological Products, Guidance for Industry (Final, December 2023).” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products.

———. 2023d. “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products: Guidance for Industry.” CDER, CBER and OCE. https://www.fda.gov/media/148910/download.

———. 2024a. “21 CFR 312.32: IND Safety Reporting.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32.

———. 2024b. “21 CFR 314.126: Adequate and Well-Controlled Studies.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.126.

———. 2024c. “FDA Adverse Event Reporting System (FAERS) Public Dashboard.” https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers-database.

———. 2024d. “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry.” Final guidance, Oncology Center of Excellence, CDER and CBER. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases.

———. 2024e. “Use of Data Monitoring Committees in Clinical Trials: Draft Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-data-monitoring-committees-clinical-trials.

———. 2025a. “Drug Development Tools: Fit-for-Purpose Initiative.” https://www.fda.gov/drugs/development-approval-process-drugs/drug-development-tools-fit-purpose-initiative.

———. 2025b. “Sponsor Responsibilities – Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Guidance for Industry.” Center for Drug Evaluation; Research; Center for Biologics Evaluation; Research. https://www.fda.gov/media/150356/download.

———. 2025c. “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological.

———. 2026a. “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products.

———. 2026b. “FDA Launches New Adverse Event Look-Up Tool.” https://www.fda.gov/news-events/press-announcements/fda-launches-new-adverse-event-look-tool.

———. 2026c. “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products: Guidance for Industry (Procedural).” https://www.fda.gov/media/172311/download.

———. 2026d. “Forms for Reporting to FDA.” https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda.

———. 2026e. “General Considerations for the Use of New Approach Methodologies in Drug Development: Guidance for Industry.” https://www.fda.gov/media/191589/download.

———. 2026f. “Master Protocols for Drug and Biological Product Development: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development.

———. 2026g. “Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products.” U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products.

———. 2026h. “Statistical Approaches to Establishing Bioequivalence: Guidance for Industry.” Center for Drug Evaluation; Research. https://www.fda.gov/media/163638/download.

———. n.d.a. “CID Case Study: A Study in Patients with Epilepsy with Myoclonic-Atonic Seizures.” https://www.fda.gov/media/172312/download.

———. n.d.b. “CID Case Study: A Study in Pediatric Patients with Multiple Sclerosis.” https://www.fda.gov/media/172313/download.

———. n.d.c. “Complex Innovative Trial Design (CID) Paired Meeting Program.” https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program.

———. n.d.d. “Complex Innovative Trial Design Meeting Program.” https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program.

———. n.d.e. “Critical Path Innovation Meetings (CPIM).” https://www.fda.gov/drugs/novel-drug-approvals-fda/critical-path-innovation-meetings-cpim.

———. n.d.f. “Drug Development Tool (DDT) Qualification Programs.” https://www.fda.gov/drugs/development-approval-process-drugs/drug-development-tool-ddt-qualification-programs.

———. n.d.g. “Model-Informed Drug Development Paired Meeting Program.” https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program.

U.S. Food and Drug Administration, CDER. n.d.a. “Complex Innovative Trial Design Case Study: Epilepsy with Myoclonic-Atonic Seizures (EMAS) Study with a Bayesian Hierarchical Model.” https://www.fda.gov/media/172312/download.

———. n.d.b. “Complex Innovative Trial Design Case Study: Pediatric Multiple Sclerosis Non-Inferiority Study with a Bayesian Analysis.” https://www.fda.gov/media/172313/download.

U.S. Food and Drug Administration, CDRH. 2015. “Summary of Safety and Effectiveness Data, Superion InterSpinous Spacer, PMA P140004.” https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140004B.pdf.

U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. 2022. “FDA Briefing Document, Vaccines and Related Biological Products Advisory Committee Meeting, September 22, 2022: RBX2660 (Fecal Microbiota Suspension for Rectal Enema), Rebiotix, Inc., BLA STN 125739.” https://www.fda.gov/media/161679/download.

U.S. Food and Drug Administration, Center for Devices and Radiological Health. 2019. “Summary of Safety and Effectiveness Data, OPTIMIZER Smart System, PMA P180036.” https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180036B.pdf.

U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 2026. “LEADER 3D: Bayesian Statistics in Rare Disease Clinical Investigations, Belimumab (Benlysta).” https://www.fda.gov/media/193802/download.

US Food and Drug Administration, Center for Biologics Evaluation and Research. 2022. “Clinical Review Memorandum: REBYOTA (Fecal Microbiota, Live-jslm), BLA 125739.” US Food and Drug Administration. https://www.fda.gov/media/164040/download.

Vickers, Andrew J., and Douglas G. Altman. 2001. “Analysing Controlled Trials with Baseline and Follow up Measurements.” BMJ 323 (7321): 1123–24. https://doi.org/10.1136/bmj.323.7321.1123.

Viele, Kert, Scott Berry, Beat Neuenschwander, Billy Amzal, Fang Chen, Nathan Enas, Brian Hobbs, et al. 2014. “Use of Historical Control Data for Assessing Treatment Effects in Clinical Trials.” Pharmaceutical Statistics 13 (1): 41–54.

Villar, Sofía S., Jack Bowden, and James Wason. 2015. “Multi-Armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges.” Statistical Science 30 (2): 199–215.

———. 2018. “Response-Adaptive Designs for Binary Responses: How to Offer Patient Benefit While Being Robust to Time Trends?” Pharmaceutical Statistics 17 (2): 182–97. https://doi.org/10.1002/pst.1845.

Villar, Sofía S., David S. Robertson, and William F. Rosenberger. 2020. “The Temptation of Overgeneralizing Response-Adaptive Randomization.” Clinical Infectious Diseases 73 (3): e842. https://doi.org/10.1093/cid/ciaa1027.

Villar, Sofía S., James Wason, and Jack Bowden. 2015. “Response-Adaptive Randomization for Multi-Arm Clinical Trials Using the Forward Looking Gittins Index Rule.” Biometrics 71 (4): 969–78. https://doi.org/10.1111/biom.12337.

Ville, Jean. 1939. Étude Critique de La Notion de Collectif. Monographies Des Probabilités 3. Paris: Gauthier-Villars.

Vovk, Vladimir, and Ruodu Wang. 2021. “E-Values: Calibration, Combination and Applications.” The Annals of Statistics 49 (3): 1736–54. https://doi.org/10.1214/20-AOS2020.

Wacholder, Sholom, Stephen Chanock, Montserrat Garcia-Closas, Laure El Ghormli, and Nathaniel Rothman. 2004. “Assessing the Probability That a Positive Report Is False: An Approach for Molecular Epidemiology Studies.” Journal of the National Cancer Institute 96 (6): 434–42. https://doi.org/10.1093/jnci/djh075.

Wald, Abraham. 1945. “Sequential Tests of Statistical Hypotheses.” The Annals of Mathematical Statistics 16 (2): 117–86.

———. 1947. Sequential Analysis. New York: John Wiley & Sons.

Wald, Abraham, and Jacob Wolfowitz. 1948. “Optimum Character of the Sequential Probability Ratio Test.” The Annals of Mathematical Statistics 19 (3): 326–39. https://doi.org/10.1214/aoms/1177730197.

Wang, Chenguang, Heng Li, Wei-Chen Chen, Nelson Lu, Ram Tiwari, Yunling Xu, and Lilly Q. Yue. 2019. “Propensity Score-Integrated Power Prior Approach for Incorporating Real-World Evidence in Single-Arm Clinical Studies.” Journal of Biopharmaceutical Statistics 29 (5): 731–48. https://doi.org/10.1080/10543406.2019.1657133.

Wang, Fei, and Alan E. Gelfand. 2002. “A Simulation-Based Approach to Bayesian Sample Size Determination for Performance Under a Given Model and for Separating Models.” Statistical Science 17 (2): 193–208. https://doi.org/10.1214/ss/1030550861.

Wang, Haiyun, and Douglas Yee. 2019. “I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer.” Current Breast Cancer Reports 11 (4): 303–10. https://doi.org/10.1007/s12609-019-00334-2.

Wang, Rui, Stephen W. Lagakos, James H. Ware, David J. Hunter, and Jeffrey M. Drazen. 2007. “Statistics in Medicine: Reporting of Subgroup Analyses in Clinical Trials.” New England Journal of Medicine 357 (21): 2189–94. https://doi.org/10.1056/NEJMsr077003.

Wang, Samuel K., and Anastasios A. Tsiatis. 1987. “Approximately Optimal One-Parameter Boundaries for Group Sequential Trials.” Biometrics 43 (1): 193–99. https://doi.org/10.2307/2531959.

Ware, James H. 1989. “Investigating Therapies of Potentially Great Benefit: ECMO.” Statistical Science 4 (4): 298–306.

Ware, James H., and Mark F. Epstein. 1985. “Comments on ‘Extracorporeal Circulation in Neonatal Respiratory Failure: A Prospective Randomized Study’.” Pediatrics 76 (5): 849–51. https://doi.org/10.1542/peds.76.5.849.

Wason, James M. S., and Thomas Jaki. 2012. “Optimal Design of Multi-Arm Multi-Stage Trials.” Statistics in Medicine 31 (30): 4269–79. https://doi.org/10.1002/sim.5513.

Wason, James M. S., and Lorenzo Trippa. 2014. “A Comparison of Bayesian Adaptive Randomization and Multi-Stage Designs for Multi-Arm Clinical Trials.” Statistics in Medicine 33 (13): 2206–21. https://doi.org/10.1002/sim.6086.

Wasserstein, Ronald L., and Nicole A. Lazar. 2016. “The ASA Statement on p-Values: Context, Process, and Purpose.” The American Statistician 70 (2): 129–33. https://doi.org/10.1080/00031305.2016.1154108.

Wassmer, Gernot, and Werner Brannath. 2016. Group Sequential and Confirmatory Adaptive Designs in Clinical Trials. Springer. https://doi.org/10.1007/978-3-319-32562-0.

Wathen, J Kyle, and Peter F Thall. 2017. “A simulation study of outcome adaptive randomization in multi-arm clinical trials.” Clinical Trials 14 (5): 432–40. https://doi.org/10.1177/1740774517692302.

Weber, Sebastian, Yue Li, John W. Seaman, Tomoyuki Kakizume, and Heinz Schmidli. 2021. “Applying Meta-Analytic-Predictive Priors with the R Bayesian Evidence Synthesis Tools.” Journal of Statistical Software 100 (19): 1–32. https://doi.org/10.18637/jss.v100.i19.

Wei, L. J. 1978. “The Adaptive Biased Coin Design for Sequential Experiments.” The Annals of Statistics 6 (1): 92–100. https://doi.org/10.1214/aos/1176344068.

Wei, L. J., and S. Durham. 1978. “The Randomized Play-the-Winner Rule in Medical Trials.” Journal of the American Statistical Association 73: 840–43.

Wen, Patrick Y., Donald A. Berry, et al. 2026. “Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.” Journal of Clinical Oncology 44 (17): 1655. https://doi.org/10.1200/jco-26-01027.

Wen, Patrick Y., Donald A. Berry, Meredith B. Buxton, Howard Colman, John de Groot, Michael Lim, Ingo Mellinghoff, James R. Perry, Michael Weller, et al. 2026. “Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.” Journal of Clinical Oncology 44 (18): 1676–86. https://doi.org/10.1200/jco-25-01137.

Westlake, W. J. 1976. “Symmetrical Confidence Intervals for Bioequivalence Trials.” Biometrics 32 (4): 741–44. https://doi.org/10.2307/2529259.

Whitehead, John. 1986. “On the Bias of Maximum Likelihood Estimation Following a Sequential Test.” Biometrika 73 (3): 573–81. https://doi.org/10.1093/biomet/73.3.573.

———. 1993. “The Case for Frequentism in Clinical Trials.” Statistics in Medicine 12 (15–16): 1405–13. https://doi.org/10.1002/sim.4780121506.

Whitehead, John, and Ian Stratton. 1983. “Group Sequential Clinical Trials with Triangular Continuation Regions.” Biometrics 39 (1): 227. https://doi.org/10.2307/2530822.

Whittle, P. 1980. “Multi-Armed Bandits and the Gittins Index.” Journal of the Royal Statistical Society: Series B 42 (2): 143–49. https://doi.org/10.1111/j.2517-6161.1980.tb01111.x.

Wijeysundera, Duminda N., Peter C. Austin, Janet E. Hux, W. Scott Beattie, and Andreas Laupacis. 2009. “Bayesian Statistical Inference Enhances the Interpretation of Contemporary Randomized Controlled Trials.” Journal of Clinical Epidemiology 62 (1): 13–21.e5. https://doi.org/10.1016/j.jclinepi.2008.07.006.

Wong, Chi Heem, Kien Wei Siah, and Andrew W. Lo. 2019. “Estimation of Clinical Trial Success Rates and Related Parameters.” Biostatistics 20 (2): 273–86. https://doi.org/10.1093/biostatistics/kxx069.

Woodcock, Janet, and Lisa M. LaVange. 2017. “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.” New England Journal of Medicine 377 (1): 62–70. https://doi.org/10.1056/NEJMra1510062.

Wouters, Olivier J., Martin McKee, and Jeroen Luyten. 2020. “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.” JAMA 323 (9): 844–53. https://doi.org/10.1001/jama.2020.1166.

Xia, H. Amy, Haijun Ma, and Bradley P. Carlin. 2011. “Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials.” Journal of Biopharmaceutical Statistics 21 (5): 1006–29. https://doi.org/10.1080/10543406.2010.520181.

Yan, Fangrong, Sumithra J. Mandrekar, and Ying Yuan. 2017. “Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.” Clinical Cancer Research 23 (15): 3994–4003. https://doi.org/10.1158/1078-0432.CCR-17-0220.

Ye, Ting, Jun Shao, Yanyao Yi, and Qingyuan Zhao. 2023. “Toward Better Practice of Covariate Adjustment in Analyzing Randomized Clinical Trials.” Journal of the American Statistical Association 118 (544): 2370–82. https://doi.org/10.1080/01621459.2022.2049278.

Yoshioka, Alan. 1998. “Use of Randomisation in the Medical Research Council’s Clinical Trial of Streptomycin in Pulmonary Tuberculosis in the 1940s.” BMJ 317 (7167): 1220–23. https://doi.org/10.1136/bmj.317.7167.1220.

Yuan, Ying, Kenneth R. Hess, Susan G. Hilsenbeck, and Mark R. Gilbert. 2016. “Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.” Clinical Cancer Research 22 (17): 4291–301. https://doi.org/10.1158/1078-0432.CCR-16-0592.

Yuan, Ying, Ruitao Lin, Daniel Li, Lei Nie, and Katherine E. Warren. 2018. “Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.” Clinical Cancer Research 24 (20): 4921–30. https://doi.org/10.1158/1078-0432.CCR-18-0246.

Yuan, Ying, Hoang Q. Nguyen, and Peter F. Thall. 2016. Bayesian Designs for Phase I-II Clinical Trials. Boca Raton, FL: Chapman; Hall/CRC.

Yuan, Ying, Heng Zhou, and Suyu Liu. 2024. “Statistical and Practical Considerations in Planning and Conduct of Dose-Optimization Trials.” Clinical Trials 21 (3): 273–86. https://doi.org/10.1177/17407745231207085.

Zampieri, Fernando G., Jonathan D. Casey, Manu Shankar-Hari, Frank E. Harrell, and Michael O. Harhay. 2021. “Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial.” American Journal of Respiratory and Critical Care Medicine 203 (5): 543–52. https://doi.org/10.1164/rccm.202006-2381CP.

Zampieri, Fernando G., Lucas P. Damiani, Jan Bakker, et al. 2020. “Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status Versus Serum Lactate Levels Among Patients with Septic Shock: A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial.” American Journal of Respiratory and Critical Care Medicine 201: 423–29. https://doi.org/10.1164/rccm.201905-0968OC.

Zelen, Marvin. 1969. “Play the Winner Rule and the Controlled Clinical Trial.” Journal of the American Statistical Association 64 (325): 131–46. https://doi.org/10.1080/01621459.1969.10500959.

———. 1974. “The Randomization and Stratification of Patients to Clinical Trials.” Journal of Chronic Diseases 27 (7–8): 365–75. https://doi.org/10.1016/0021-9681(74)90015-0.

———. 1979. “A New Design for Randomized Clinical Trials.” New England Journal of Medicine 300 (22): 1242–45. https://doi.org/10.1056/NEJM197905313002203.

Zhou, Heng, J. Jack Lee, and Ying Yuan. 2017. “BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.” Statistics in Medicine 36 (21): 3302–14. https://doi.org/10.1002/sim.7338.

Zhou, Heng, Ying Yuan, and Lei Nie. 2018. “Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.” Clinical Cancer Research 24 (18): 4357–64. https://doi.org/10.1158/1078-0432.CCR-18-0168.

Zhou, Xian, Suyu Liu, Edward S. Kim, Roy S. Herbst, and J. Jack Lee. 2008. “Bayesian Adaptive Design for Targeted Therapy Development in Lung Cancer.” Clinical Trials 5 (3): 181–93. https://doi.org/10.1177/1740774508091815.

Zia, Mohammad I., Lillian L. Siu, Gregory R. Pond, and Eric X. Chen. 2005. “Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens.” Journal of Clinical Oncology 23 (28): 6982–91. https://doi.org/10.1200/JCO.2005.06.679.

Zorych, Ivan, David Madigan, Patrick Ryan, and Andrew Bate. 2013. “Disproportionality Methods for Pharmacovigilance in Longitudinal Observational Databases.” Statistical Methods in Medical Research 22 (1): 39–56. https://doi.org/10.1177/0962280211403602.